[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 198
1. Radhi J, Tse F, Marcaccio M: Papillocystic variant of acinar cell pancreatic carcinoma. J Oncol; 2010;2010:242016
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillocystic variant of acinar cell pancreatic carcinoma.
  • Acinar cell pancreatic carcinoma is a rare solid malignant neoplasm.
  • We report a large 10 cm pancreatic tumor with papillocystic pathology features involving the pancreatic head.
  • The growth pattern of these tumors could be mistaken for intraductal papillary mucinous tumors or other pancreatic cystic neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Cancer Imaging. 2006;6:60-71 [16861136.001]
  • [Cites] J Gastrointest Surg. 2009 Aug;13(8):1495-502 [19495891.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2078-86 [18836784.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):363-70 [17325477.001]
  • (PMID = 20204128.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2831459
  •  go-up   go-down


2. Sanati S, Watson MA, Salavaggione AL, Humphrey PA: Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol; 2009 Oct;22(10):1273-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.
  • Ductal adenocarcinoma is an uncommon variant of prostatic adenocarcinoma with a generally more aggressive clinical course than usual acinar adenocarcinoma.
  • However, the molecular distinction between ductal and acinar adenocarcinomas is not well characterized.
  • The aim of this investigation was to evaluate the relatedness of ductal versus acinar prostatic adenocarcinoma by comparative gene expression profiling.
  • Archived, de-identified, snap frozen tumor tissue from 5 ductal adenocarcinomas, 3 mixed ductal-acinar adenocarcinomas, and 11 acinar adenocarcinomas cases were analyzed.
  • All cases of acinar and ductal adenocarcinomas were matched by Gleason grade.
  • RNA from whole tissue sections of the 5 ductal and 11 acinar adenocarcinomas cases were subjected to gene expression profiling on Affymetrix U133Plus2 microarrays.
  • Independently, laser-capture microdissection was also performed on the three mixed ductal-acinar cases and five pure acinar cases to isolate homogeneous populations of ductal and acinar carcinoma cells from the same tumor.
  • Seven of these laser-capture microdissected samples (three ductal and four acinar cell populations) were similarly analyzed on U133Plus2 arrays.
  • Analysis of data from whole sections of ductal and acinar carcinomas identified only 25 gene transcripts whose expression was significantly and at least two-fold different between ductal and acinar adenocarcinomas.
  • A similar analysis of microdissected cell populations identified 10 transcripts, including the prolactin receptor, with more significant differences in expression of 5- to 27-fold between ductal and acinar adenocarcinomas cells.
  • Overexpression of prolactin receptor protein in ductal versus acinar adenocarcinoma was confirmed by immunohistochemistry in an independent set of tumors.
  • We conclude that ductal and acinar adenocarcinomas of the prostate are strikingly similar at the level of gene expression.
  • However, several of the genes identified in this study, including the prolactin receptor, represent targets for further investigations on the molecular basis for histomorphological and clinical behavioral differences between acinar and ductal adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Acinar Cell / genetics. Carcinoma, Ductal / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Cluster Analysis. Humans. Immunohistochemistry. Male. Microdissection. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Prostatectomy. RNA, Messenger / analysis. Receptors, Prolactin / analysis. Receptors, Prolactin / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633648.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Prolactin
  •  go-up   go-down


3. Svrcek M, Lesurtel M, Lewin M, Afchain P, Fabre M, Scoazec JY, Parc R, Fléjou JF: [Acinar cell carcinoma of the pancreas with predominant intraductal growth: report of a case]. Gastroenterol Clin Biol; 2007 May;31(5):543-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinar cell carcinoma of the pancreas with predominant intraductal growth: report of a case].
  • [Transliterated title] Carcinome à cellules acineuses du pancréas, de développement essentiellement intracanalaire: à propos d'un cas.
  • Acinar cell carcinoma (ACC) of the pancreas accounts for approximately 1% of all exocrine pancreatic tumours.
  • This tumour was revealed by epigastric pain and weight loss.
  • There was a marked dilatation of the main pancreatic duct upstream, with tumour spreading within this duct.
  • On the pancreaticoduodenectomy specimen, the dilated main pancreatic duct (2.5 cm in diameter) was filled by an exophytic tumour.
  • These rare forms of ACC can be confused with intraductal papillary-mucinous neoplasms.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Pancreatic Ducts / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Endosonography. Humans. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Radiography, Abdominal. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541347.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Peng HQ, Darwin P, Papadimitriou JC, Drachenberg CB: Liver metastases of pancreatic acinar cell carcinoma with marked nuclear atypia and pleomorphism diagnosed by EUS FNA cytology: a case report with emphasis on FNA cytological findings. Cytojournal; 2006;3:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastases of pancreatic acinar cell carcinoma with marked nuclear atypia and pleomorphism diagnosed by EUS FNA cytology: a case report with emphasis on FNA cytological findings.
  • BACKGROUND: Acinar cell carcinoma of the pancreas is a rare neoplasm.
  • Although this tumor has been well characterized histologically, the morphological patterns in Fine Needle Aspiration Cytology have not been well defined.
  • Unlike ductal adenocarcinomas, endocrine tumors, and solid pseudopapillary tumors of the pancreas with their characteristic FNA cytological features, acinar cell carcinomas pose a particular diagnostic challenge by sharing many cytomorphologic features with endocrine tumors of the pancreas.
  • FNA cytology revealed abundant, loosely cohesive clusters of malignant epithelial cells with vaguely acinar and trabecular formations.
  • Scattered, strikingly large tumor cells with giant nuclei, prominent mitoses and associated necrosis were evident.
  • A pancreatic endocrine tumor was suspected initially, but acinar cell carcinoma of the pancreas was confirmed by immunohistochemistry, cytochemical and ultrastructural studies.
  • CONCLUSION: We describe a case of pancreatic acinar cell carcinoma with unusual cytomorphologic features mimicking an endocrine tumor of pancreas, encountered in endoscopic ultrasound-guided fine needle aspiration of a metastatic liver mass and discuss the diagnostic approach for this unusual pancreatic tumor in fine needle aspiration cytology.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2005 Aug;33(2):100-5 [16007666.001]
  • [Cites] Endoscopy. 2003 Sep;35(9):743-9 [12929021.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Gastroenterol. 2005 Sep;40(9):907-11 [16211348.001]
  • [Cites] Cytopathology. 2006 Feb;17(1):34-41 [16417563.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):367-72 [16604543.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):180-5 [16634071.001]
  • [Cites] Acta Cytol. 1989 Mar-Apr;33(2):157-63 [2467480.001]
  • [Cites] Arch Pathol Lab Med. 1983 Oct;107(10):552-4 [6688519.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):889-93 [8249508.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1227-30 [8960033.001]
  • [Cites] Diagn Cytopathol. 1997 Feb;16(2):112-6 [9067100.001]
  • [Cites] Endoscopy. 1997 Nov;29(9):854-8 [9476770.001]
  • [Cites] Gastrointest Endosc. 1998 Feb;47(2):121-7 [9512275.001]
  • [Cites] Endoscopy. 1998 Aug;30 Suppl 1:A159-60 [9765114.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3 [10367874.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):341-8 [12789912.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):357-61 [10462656.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • (PMID = 17196112.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779360
  •  go-up   go-down


5. Distler M, Rückert F, Dittert DD, Stroszczynski C, Dobrowolski F, Kersting S, Grützmann R: Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy. World J Surg Oncol; 2009;7:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy.
  • BACKGROUND: Acinar cell carcinoma (ACC) represents only 1-2% of pancreatic cancers and is a very rare malignancy.
  • MRI-imaging showed a tumor within the head of the pancreas concomitant with Serum-Lipase and CA19-9.
  • Endosonographic fine needle biopsy confirmed an acinar cell carcinoma.
  • Laparotomy presented an locally advanced tumor with venous infiltration that was consequently deemed unresectable.
  • Twelve months later, the patient was in stable condition, and CT-scanning showed an obvious reduction in the size of the tumor.
  • Histopathological examination gave evidence of a diffuse necrotic ACC-tumor, all resection margins were found to be negative.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / surgery. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Pathol Res Pract. 2002;198(12):777-83 [12608654.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Radiology. 1979 Feb;130(2):345-6 [760147.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Dig Surg. 1999;16(1):76-9 [9949272.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] JOP. 2007;8(6):783-9 [17993731.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • (PMID = 19239719.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2657786
  •  go-up   go-down


6. Kubisch CH, Logsdon CD: Secretagogues differentially activate endoplasmic reticulum stress responses in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol; 2007 Jun;292(6):G1804-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretagogues differentially activate endoplasmic reticulum stress responses in pancreatic acinar cells.
  • The present study aimed to examine the effects of different types and concentrations of secretagogues on acinar cell function and specific components of the UPR.
  • [MeSH-minor] Amylases / metabolism. Animals. Basic-Leucine Zipper Transcription Factors / genetics. Basic-Leucine Zipper Transcription Factors / metabolism. Cells, Cultured. DNA-Binding Proteins. Dose-Response Relationship, Drug. Enzyme Activation. Heat-Shock Proteins / metabolism. Male. Molecular Chaperones / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Phosphorylation. RNA Splicing. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Transcription Factor CHOP / genetics. Transcription Factor CHOP / metabolism. Transcription Factors. Trypsin / metabolism. Trypsinogen / metabolism. eIF-2 Kinase / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431218.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-52067
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / DNA-Binding Proteins; 0 / Heat-Shock Proteins; 0 / Hspa5 protein, rat; 0 / Molecular Chaperones; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / regulatory factor X transcription factors; 119733-42-5 / JMV 180; 147336-12-7 / Transcription Factor CHOP; 9002-08-8 / Trypsinogen; EC 2.7.10.- / PERK kinase; EC 2.7.11.1 / eIF-2 Kinase; EC 3.2.1.- / Amylases; EC 3.4.21.4 / Trypsin; M03GIQ7Z6P / Sincalide; PX9AZU7QPK / Bombesin
  •  go-up   go-down


7. Azúa-Romeo J, Sánchez-Garnica JC, Azúa-Blanco J, Tovar-Lázaro M: DNA quantification as prognostic factor in a case of acinar cell carcinoma of the parotid gland, diagnosed by FNA. Med Oral Patol Oral Cir Bucal; 2005 Aug-Oct;10(4):289-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA quantification as prognostic factor in a case of acinar cell carcinoma of the parotid gland, diagnosed by FNA.
  • Fine needle aspiration cytology was performed, diagnosing of compatible with acinar cell carcinoma, thus DNA quantification by image cytometry was carried out.
  • [MeSH-major] Carcinoma, Acinar Cell / genetics. Parotid Neoplasms / genetics
  • [MeSH-minor] Adult. Aneuploidy. Biopsy, Fine-Needle. DNA Replication. DNA, Neoplasm / analysis. Humans. Image Cytometry. Male. Neoplasm Invasiveness. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16056182.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


8. Pascual Mateo C, Luján Galán M, Rodríguez García N, Llanes González L, Berenguer Sánchez A: [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer]. Actas Urol Esp; 2008 Jul-Aug;32(7):680-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer].
  • [Transliterated title] Significado clínico de la neoplasia intraepitelial prostática y de la proliferación acinar focal atípica: relación con el cáncer de próstata.
  • INTRODUCTION: Prostatic intraepithelial neoplasia (PIN) and atypical small acinar proliferation (ASAP) in the setting of prostatic needle biopsies are considered premalignant although questions still remain.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cell Proliferation. Humans. Male. Middle Aged. Retrospective Studies


9. Kinkor Z, Skálová A: [Acinic cell-like differentiation in invasive ductal carcinoma and in ductal hyperplasia of the breast--report of two cases]. Cesk Patol; 2005 Jan;41(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell-like differentiation in invasive ductal carcinoma and in ductal hyperplasia of the breast--report of two cases].
  • [Transliterated title] "Acinic cell-like" diferenciace v invazivním duktálním karcinomu a duktální hyperlazii mlécné zlázy--popis dvou prípadů.
  • Described are two epithelial lesions of the breast displaying extremely rare, widespread acinic cell-like differentiation (metaplasia).
  • Two women, 70 and 40-year-old, one with invasive ductal papillocarcinoma, the other one with conventional intraductal hyperplasia without atypia, both demonstrated massive diffuse, PAS positive, granular eosinophilic transformation of the cell cytoplasm.
  • This unusual cell appearance closely simulated acinar cells in normal serous salivary gland/acinic cell carcinoma or Paneth cells.
  • Both extensive expression of lysozyme and finding of numerous zymogen granules ultrastructurally confirmed the acinic cell-like fenotype.
  • Discussed is differential diagnosis of the breast neoplasm containing overt eosinophilic and granular cytoplasm.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Acinar Cell / pathology. Carcinoma, Ductal, Breast / pathology


10. Komorski JA, Nienartowicz JM: [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis]. Otolaryngol Pol; 2009 Sep-Oct;63(5):442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis].
  • [Transliterated title] Acinic cell carcinoma ślinianki przyusznej o nietypowym obrazie klinicznym i niekorzystnym przebiegu.
  • In the case of neck tumours, these are unfortunately late signs, but in patients with a primary neoplastic focus within the head and neck, neck tumour is often the first sign of the disease.
  • The authors describe a clinical case of neck tumour with initially unclear etiology.
  • The preoperative diagnostics including ultrasonography, thin-needle puncture, MRI, carotid angiography and videostroboscopy was significant for surgical treatment planning; yet it was the intraoperative clinical picture which indicated that the tumour derived from the inferior parotid pole.
  • The histopathological examination confirmed non-cornifying basal cell epithelioma only in the essential lesion with no metastases to lymph nodes and surrounding tissue margins free of infiltrates.
  • Two and a half years after the procedure, the patient presented with a tumour localized on the front thoracic wall and two rapidly enlarging tumours in the nape of the neck.
  • In the collected specimen of the tumour on the front thoracic wall, a diagnosis of acinic cell carcinoma was made.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Head and Neck Neoplasms / secondary. Humans. Male. Neck Dissection / methods. Neoplasm Staging. Palliative Care. Prognosis. Thoracic Wall / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169911.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS: Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol; 2010 Apr;34(4):510-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
  • BACKGROUND: Pancreatic acinar cell carcinomas (ACCs) are clinically and pathologically distinct from pancreatic ductal adenocarcinomas (PDAs).
  • All cases showed significant evidence of both acinar and ductal differentiation, estimated to be at least 25% of the neoplastic cells, and 3 cases in addition had endocrine differentiation in more than 25% of cells.
  • Five cases were predominately acinar with intracellular and sometimes extracellular mucin ("mucinous acinar cell carcinoma" pattern).
  • Six cases seemed more mixed with areas recapitulating typical PDAs whereas the other portions of the tumors seemed akin to typical acinar cell carcinomas ("combined acinar and ductal" pattern).
  • CONCLUSION: Despite the early embryologic divergence of acinar and ductal cell lineages, rare pancreatic tumors have both acinar and ductal differentiation, usually predominantly the former.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Islet Cell / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Combined Modality Therapy. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucins / metabolism. Mutation. Neoplasms, Multiple Primary. New York / epidemiology. Pancreatectomy. Proto-Oncogene Proteins / genetics. Survival Rate. Virginia / epidemiology. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182344.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Mucins; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


12. Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, Merchant N, Johnson CS, Lillemoe KD, Grützmann R: Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg; 2009 Aug;13(8):1495-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinoma: a multi-institutional study.
  • INTRODUCTION: The presentation and outcome of patients with acinar cell carcinoma (ACC) of the pancreas compared to the more common ductal cell adenocarcinoma (DCA) may be distinct.
  • Mean tumor size was 5.3 cm.
  • American Joint Commission on Cancer tumor stages were stage I (two), stage II (eight), stage III (four), and stage IV (three).
  • This is in contrast to 1,608 patients with ductal cell adenocarcinoma who underwent resection identified from recent literature reports where the average median survival was only 24 months.
  • CONCLUSION: Acinar cell carcinoma of the pancreas is rare and appears to have a presentation and outcome distinct from the more common pancreatic DCA.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Follow-Up Studies. Germany / epidemiology. Humans. Incidence. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pancreatectomy / methods. Prognosis. Prospective Studies. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495891.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Kawakami H, Kuwatani M, Onodera M, Hirano S, Kondo S, Nakanishi Y, Itoh T, Asaka M: Primary acinar cell carcinoma of the ampulla of Vater. J Gastroenterol; 2007 Aug;42(8):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the ampulla of Vater.
  • Acinar cell carcinoma of the pancreatobiliary system is a relatively rare malignant neoplasm arising usually in the pancreatic parenchyma.
  • The patient underwent a curative surgical operation, and histopathological examination revealed that the tumor was confined to the ampulla of Vater with no continuity to the pancreatic parenchyma.
  • The tumor cells showed acinar or tubular arrangement with eosinophilic to basophilic granular cytoplasm, findings identical to those of acinar cell carcinoma of the pancreas.
  • Immunohistochemically, the tumor cells were positive for lipase.
  • From these findings, we concluded that the tumor was primary acinar cell carcinoma arising in the ampulla of Vater, probably originating from heterotopic pancreatic tissue.
  • This is the first reported case of primary acinar cell carcinoma in the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Acinar Cell / diagnosis. Common Bile Duct Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701134.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Sorscher SM: Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report. Eur J Cancer Care (Engl); 2009 May;18(3):318-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
  • Acinar cell carcinoma of the pancreas is rare tumour with a generally poor prognosis.
  • There are very few reports of tumour regression following chemotherapy.
  • In this case report, a patient with metastatic acinar cell carcinoma in the liver developed progressive disease after cisplatin/etoposide and then had progressive disease after weekly paclitaxel chemotherapy.
  • However, his tumour then responded to gemcitibine/5-flourouracil/leucovorin chemotherapy.
  • Herein, previously described chemotherapy regimens used for this rare tumour are reviewed.
  • This case represents the first reported metastatic acinar cell carcinoma responding to this regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Treatment Outcome. Vitamin B Complex / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445023.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 12001-76-2 / Vitamin B Complex; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Yamaguchi R, Okabe Y, Jimi A, Shiota K, Kodama T, Naito Y, Yasunaga M, Kinoshita H, Kojiro M: Pancreatic acinar cell carcinoma extending into the common bile and main pancreatic ducts. Pathol Int; 2006 Oct;56(10):633-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinoma extending into the common bile and main pancreatic ducts.
  • Acinar cell carcinoma (ACC) of the pancreas is relatively rare, accounting for only approximately 1% of all exocrine pancreatic tumors.
  • Magnetic resonance cholangiopancreatography showed defect of the lower common bile duct (CBD) due to obstruction by the tumor cast.
  • Histopathologically, the pancreatic head tumor invaded the main pancreatic duct (MPD) and CBD with extension into the CBD in a form of tumor cast.
  • The tumor cells consisted of a solid proliferation with abundant eosinophilic cytoplasm and round nuclei in an acinar and trabecular fashion.
  • Histopathologically, the tumor was encapsulated by fibrous capsule and had extensive central necrosis with solid areas in the tumor periphery, and invaded with extension into the MPD in a form of tumor cast.
  • The tumor cells resembled acinar cells in solid growths.
  • Two resected cases of ACC with unusual tumor extension into the CBD and the MPD, respectively, are reported.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Common Bile Duct / pathology. Common Bile Duct Neoplasms / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984622.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


16. Suzuki A, Sakaguchi T, Morita Y, Oishi K, Fukumoto K, Inaba K, Takehara Y, Baba S, Suzuki S, Konno H: Long-term survival after a repetitive surgical approach in a patient with acinar cell carcinoma of the pancreas and recurrent liver metastases: report of a case. Surg Today; 2010 Jul;40(7):679-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after a repetitive surgical approach in a patient with acinar cell carcinoma of the pancreas and recurrent liver metastases: report of a case.
  • Acinar cell carcinoma is a relatively rare malignant neoplasm, which represents 1%-2% of all pancreatic exocrine tumors.
  • This report concerns a case of a long-term survivor of metastatic acinar cell carcinoma who was successfully treated with repetitive surgery.
  • A 62-year-old man underwent a distal pancreatectomy for a pancreatic tumor, which was histologically diagnosed as an acinar cell carcinoma.
  • The tumor recurred in the liver three times within 41 months.
  • Although no consensus has been reached on surgery for metastatic acinar cell carcinoma, the current case has important implications for establishing an appropriate treatment strategy.
  • [MeSH-major] Carcinoma, Acinar Cell / surgery. Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Metastasis. Reoperation. Survivors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20582524.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Szlávik V, Vág J, Markó K, Demeter K, Madarász E, Oláh I, Zelles T, O'Connell BC, Varga G: Matrigel-induced acinar differentiation is followed by apoptosis in HSG cells. J Cell Biochem; 2008 Jan 1;103(1):284-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrigel-induced acinar differentiation is followed by apoptosis in HSG cells.
  • It has been shown that a human salivary gland cell line (HSG) is capable of differentiation into gland-like structures, though little is known of how morphological features are formed or controlled.
  • Here we investigated the changes in cell proliferation and apoptosis upon terminal differentiation of HSG cells in Matrigel, an extracellular matrix derivative.
  • Results of these studies demonstrate that cytodifferentiation of HSG cells to an acinar phenotype is accompanied first by a decrease of cell proliferation and then by a massive programmed cell death, affected by multiple signal transduction pathways.
  • Thus, Matrigel alone is insufficient for the full maturation and long term survival of the newly formed acini: the presence of other factors is necessary to complete the acinar differentiation of HSG cells.
  • [MeSH-major] Apoptosis / drug effects. Cell Differentiation / drug effects. Collagen / pharmacology. Laminin / pharmacology. Proteoglycans / pharmacology. Salivary Glands / cytology. Salivary Glands / drug effects
  • [MeSH-minor] Annexins / metabolism. Caspase 3 / metabolism. Cell Line. Cell Shape / drug effects. DNA / biosynthesis. Drug Combinations. Humans. Inhibitor of Apoptosis Proteins. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Protein Binding. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17541949.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 071268/Z/03/Z,2003
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexins; 0 / BIRC5 protein, human; 0 / Drug Combinations; 0 / Inhibitor of Apoptosis Proteins; 0 / Laminin; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-49-2 / DNA; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


18. Azuma M, Ashida Y, Tamatani T, Motegi K, Takamaru N, Ishimaru N, Hayashi Y, Sato M: Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren's syndrome. J Rheumatol; 2006 May;33(5):912-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren's syndrome.
  • OBJECTIVE: Our previous study suggested that suppression by cepharanthin of tumor necrosis factor-a (TNF-a)-induced matrix metalloproteinase-9 (MMP-9) could prevent destruction of the acinar structure in the salivary glands of patients with Sjögren's syndrome (SS).
  • In this study, we observed that in vivo administration of cepharanthin prevented severe damage to acinar tissues in the murine model of human SS.
  • The apoptotic cell death of acinar cells was determined.
  • RESULTS: Although extensive mononuclear cell infiltration and destruction of acinar tissue in salivary and lacrimal glands were observed in control mice, significant improvement of these lesions was evident in mice treated with cepharanthin.
  • Immunohistochemical analysis revealed that p65, phosphorylated IkB-a, and MMP-9 were more strongly stained in the acinar cells of control mice than in cepharanthin-treated mice.
  • Although no staining for type IV collagen was observed in the acinar tissues of control mice, continuity of staining for type IV collagen was observed in acinar tissues of cepharanthin-treated mice.
  • Destruction of acinar tissues was attributed to the induction of apoptosis, suggesting that cepharanthin inhibits apoptosis by suppressing phosphorylation of IkB-a, followed by prevention of MMP-9 activation.
  • CONCLUSION: Our findings suggest that cepharanthin may be a promising agent for use in preventing destruction of acinar tissues in murine SS.
  • [MeSH-minor] Animals. Apoptosis. Benzylisoquinolines. Carrier Proteins / analysis. Collagen Type IV / analysis. Female. I-kappa B Proteins / analysis. Immunohistochemistry. Matrix Metalloproteinase 9 / analysis. Mice. Mice, Mutant Strains. Neoplasm Proteins / analysis. Transcription Factor RelA

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16652422.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Benzylisoquinolines; 0 / Carrier Proteins; 0 / Collagen Type IV; 0 / I-kappa B Proteins; 0 / Neoplasm Proteins; 0 / Rela protein, mouse; 0 / Transcription Factor RelA; 139874-52-5 / NF-kappaB inhibitor alpha; 7592YJ0J6T / cepharanthine; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


19. Yang TM, Han SC, Wu CJ, Mo LR: Acinar cell carcinomas with exophytic growth and intraductal pancreatic duct invasion: peculiar multislice computed tomographic picture. J Hepatobiliary Pancreat Surg; 2009;16(2):238-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinomas with exophytic growth and intraductal pancreatic duct invasion: peculiar multislice computed tomographic picture.
  • MSCT showed 8.4 cm well-enhancing exophytic tumor of the pancreatic head which also protruded into the duodenum.
  • The pathological diagnosis was acinar cell carcinoma (ACC) originating in the pancreatic head and directly invading through the duodenal wall and the main pancreatic duct, without any lymph node involvement.
  • [MeSH-major] Carcinoma, Acinar Cell / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Invasiveness. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183830.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M: Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas; 2007 Jul;35(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society.
  • OBJECTIVES: Acinar cell carcinoma (ACC) of the pancreas is a rare tumor, and many aspects remain unclear because no large-scale clinical studies have been conducted.
  • RESULTS: Although ACC has been associated with advanced stage and poor prognosis, this tumor was resectable in 76.5% of the patients, and the 5-year survival rate after resection was favorable, being 43.9%.
  • [MeSH-major] Carcinoma, Acinar Cell / mortality. Pancreatic Neoplasms / mortality. Registries / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575544.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Ambrosini-Spaltro A, Potì O, De Palma M, Filotico M: Pancreatic-type acinar cell carcinoma of the stomach beneath a focus of pancreatic metaplasia of the gastric mucosa. Hum Pathol; 2009 May;40(5):746-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic-type acinar cell carcinoma of the stomach beneath a focus of pancreatic metaplasia of the gastric mucosa.
  • Acinar cell carcinoma is an uncommon type of carcinoma of the pancreas that can exceptionally arise in ectopic pancreatic tissue.
  • Herein, we report a case of a 52-year-old man with pancreatic-type acinar cell carcinoma of the stomach and concomitant pancreatic metaplasia of the adjacent nonneoplastic gastric mucosa.
  • There was neither clinical nor radiographic evidence of a tumor in the pancreas itself.
  • Macroscopically, an ulcerated tumor, measuring 4 x 1.7 cm, was found in the distal antrum.
  • Microscopically, the biopsy and the surgical specimen revealed a neoplasm with a predominantly trabecular architecture composed of moderately atypical cells with finely dispersed chromatin and indistinct nucleoli.
  • The neoplastic cells and those of the adjacent metaplastic mucosa were both strongly immunoreactive for alpha-1-antitrypsin, consistent with pancreatic acinar cell differentiation.
  • Ectopic pancreatic-type acinar cell carcinoma is an extremely rare condition, having been previously reported only in 5 occasions, none of them in association with pancreatic acinar cell metaplasia of the gastric mucosa.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Gastric Mucosa / pathology. Pancreas / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation. Humans. Male. Metaplasia / pathology. Middle Aged. alpha 1-Antitrypsin / biosynthesis


22. Ban D, Shimada K, Sekine S, Sakamoto Y, Kosuge T, Kanai Y, Hiraoka N: Pancreatic ducts as an important route of tumor extension for acinar cell carcinoma of the pancreas. Am J Surg Pathol; 2010 Jul;34(7):1025-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ducts as an important route of tumor extension for acinar cell carcinoma of the pancreas.
  • Acinar cell carcinoma (ACC) of the pancreas is very rare, which usually grows expansively.
  • We reviewed the detailed gross and histologic features of 13 cases of ACC, of which 7 (54%) showed intraductal polypoid growth (IPG) of the tumor in the large pancreatic ducts with a mean IPG length of 24.8 mm.
  • Comparison of the clinicopathologic characteristics showed that ACC with IPG had less infiltrative features including lymphatic, venous, and neural invasion, formation of tumor thrombus in the portal vein, nodal metastasis, and invasion beyond the pancreas to the surrounding organs; death in only 1 case (14%) of ACC with IPG was the result of ACC itself.
  • In contrast, ACC without IPG frequently showed more infiltrative growth, and was the cause of death in 50% of patients with this type of tumor.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Invasiveness. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534994.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Lim JW, Song JY, Seo JY, Kim H, Kim KH: Role of pancreatitis-associated protein 1 on oxidative stress-induced cell death of pancreatic acinar cells. Ann N Y Acad Sci; 2009 Aug;1171:545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of pancreatitis-associated protein 1 on oxidative stress-induced cell death of pancreatic acinar cells.
  • Previously we showed that oxidative stress induces apoptosis of pancreatic acinar cells with nuclear loss of DNA repair proteins.
  • In this study, we investigated the role of PAP-1 on oxidative stress-induced cell death of pancreatic acinar AR42J cells.
  • PAP-1 mRNA expression and cell viability were determined.
  • Cell viability decreased with the concentration of glucose oxides delivered to the cells that had received glucose.
  • Cell death caused by oxidative stress was inhibited in the cells transfected with PAP-1 S cDNA, but it increased in the cells transfected with PAP-1 AS cDNA.
  • These results indicate that PAP-1 may be a defensive gene for oxidative stress-induced cell death of pancreatic acinar cells.
  • [MeSH-major] Antigens, Neoplasm / physiology. Apoptosis / physiology. Biomarkers, Tumor / physiology. Lectins, C-Type / physiology. Oxidative Stress / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / physiology. DNA, Antisense / genetics. DNA, Complementary / genetics. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723102.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Antisense; 0 / DNA, Complementary; 0 / Lectins, C-Type; 0 / RNA, Messenger; 0 / pancreatitis-associated protein
  •  go-up   go-down


24. Imamura M, Kimura Y, Ito H, Nobuoka T, Koito K, Sasaki A, Hirata K: Acinar cell carcinoma of the pancreas with intraductal growth: report of a case. Surg Today; 2009;39(11):1006-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas with intraductal growth: report of a case.
  • Acinar cell carcinomas (ACCs) of the pancreas are rare neoplasms, accounting for approximately 1% of all exocrine pancreatic tumors.
  • This type of tumor is known to be aggressive, although the survival rates are somewhat better than they are for ductal carcinoma.
  • The tumor tends to present nonspecific symptoms.
  • [MeSH-major] Carcinoma, Acinar Cell / surgery. Neoplasm Invasiveness. Pancreatectomy / methods. Pancreatic Ducts / pathology. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882327.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Mataki Y, Shinchi H, Kurahara H, Maemura K, Minami K, Setoyama T, Ueno S, Sakoda M, Yamamoto T, Takao S, Natsugoe S: [A case of acinar cell carcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration prior to surgical treatment]. Nihon Shokakibyo Gakkai Zasshi; 2010 Aug;107(8):1328-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of acinar cell carcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration prior to surgical treatment].
  • Endoscopic ultrasound guided fine-needle aspiration (EUS-FNA) revealed acinar cell carcinoma (ACC).
  • ACC of the pancreas is extremely rare, occurring in approximately 1% of all cases of pancreatic neoplasm.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Acinar Cell / pathology. Endosonography. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693758.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 26
  •  go-up   go-down


26. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, Choti MA, Wolfgang CL: Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg; 2008 Jun;12(6):1061-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature.
  • INTRODUCTION: Acinar cell carcinoma (ACC) is a rare, malignant neoplasm with a generally poor prognosis.
  • MATERIALS AND METHODS: The Johns Hopkins pathology prospective database was reviewed from 1988 to 2006 to identify patients with pancreatic neoplasms possessing features of acinar cell differentiation.
  • Median tumor size was 3.9 cm with 12 patients found to have stage IIB disease or worse.
  • CONCLUSION: Acinar cell carcinomas are rare, aggressive neoplasms that are difficult to diagnose and treat.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957440.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Mansfield A, Tafur A, Smithedajkul P, Corsini M, Quevedo F, Miller R: Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas; 2010 Oct;39(7):972-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mayo Clinic experience with very rare exocrine pancreatic neoplasms.
  • OBJECTIVES: Limited data are available to guide the management of very rare exocrine neoplasms of the pancreas (VREP).
  • The most commonly identified neoplasms were acinar cell carcinoma (n = 15), small cell carcinoma (n = 12), and squamous cell carcinoma (n = 8).
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / therapy. Rare Diseases / mortality. Rare Diseases / therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Acinar Cell / mortality. Carcinoma, Small Cell / mortality. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622706.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, Goggins M, Hruban RH, Eshleman JR: KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res; 2009 Feb;7(2):230-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
  • Pancreatic intraepithelial neoplasia (PanIN) is a precursor to invasive ductal adenocarcinoma of the pancreas.
  • Observations made in genetically engineered mouse models suggest that the acinar/centroacinar compartment can give rise to ductal neoplasia.
  • To integrate findings in mice and men, we examined human acinar cells, acinar-ductal metaplasia (ADM) lesions, and PanINs for KRAS2 gene mutations.
  • Stromal cells, acinar cells, ADMs, and PanINs were separately isolated using laser capture microdissection.
  • All 31 microdissected foci of acinar cells were KRAS2 gene wild-type, as were all 12 isolated ADM lesions lacking an associated PanIN.
  • Ductal neoplasms of the human pancreas, as defined by KRAS2 gene mutations, do not appear to arise from acinar cells.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):7-11 [14749121.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):953-6 [8439969.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):227-31 [8536861.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):141-7 [15782177.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):14-7 [16397208.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):211-3 [17349578.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):353-360 [18075308.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • (PMID = 19208745.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-15; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS89589; NLM/ PMC2708114
  •  go-up   go-down


29. Vakiani E, Young RH, Carcangiu ML, Klimstra DS: Acinar cell carcinoma of the pancreas metastatic to the ovary: a report of 4 cases. Am J Surg Pathol; 2008 Oct;32(10):1540-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas metastatic to the ovary: a report of 4 cases.
  • We report 4 cases of acinar cell carcinoma of the pancreas, 3 presenting as metastases in the ovary, the first report of this circumstance, which may pose a broad differential diagnosis and caused significant diagnostic difficulty in all the cases.
  • In 3 cases, the ovarian tumors were detected before the pancreatic tumor; in 1 case, a large abdominal mass and ovarian tumors were discovered synchronously.
  • The ovarian tumors were large, solid, white-tan on gross examination, and bilateral in 3 cases; the single case involving only 1 ovary had 2 discrete masses of tumor.
  • Microscopic examination showed highly cellular neoplasms with a small amount of fibrous stroma.
  • Two cases had a predominant acinar growth pattern of cells with brightly eosinophilic, granular cytoplasm.
  • The main differential diagnostic consideration was well-differentiated neuroendocrine neoplasm (carcinoid tumor); positive immunostaining with antibodies against chymotrypsin and trypsin and negative immunostaining with antibodies against synaptophysin and chromogranin helped exclude this diagnosis.
  • We observed focal alpha-inhibin immunostaining in 2 cases, which may represent a potential diagnostic pitfall, as a Sertoli cell tumor or unusual granulosa cell tumor may also enter the differential diagnosis.
  • Inclusion of antibodies against the pancreatic enzymes chymotrypsin and trypsin in the immunohistochemical panel is critical in establishing the correct diagnosis and should be considered when evaluating ovarian tumors with architectural (mainly acinar) and cytologic (granular eosinophilic cytoplasm) characteristics that should bring a metastatic acinar cell carcinoma into consideration.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Ovarian Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724247.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Klimstra DS: Nonductal neoplasms of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S94-112
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonductal neoplasms of the pancreas.
  • Although the majority of pancreatic neoplasms are infiltrating ductal adenocarcinomas or other neoplasms with ductal differentiation, neoplasms with acinar, endocrine, mixed, or uncertain differentiation constitute a diverse and distinctive group.
  • The most common and best-characterized nonductal neoplasms are pancreatic endocrine neoplasm, acinar cell carcinoma, pancreatoblastoma, and solid pseudopapillary neoplasm.
  • This review details the clinical and pathologic features of these nonductal neoplasms, highlighting diagnostic criteria including the use of specific immunohistochemical stains to define the cellular differentiation of the neoplasms.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenoma, Islet Cell / pathology. Carcinoma, Acinar Cell / pathology. Carcinoma, Islet Cell / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486055.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Suh SI, Seol HY, Kim TK, Lee NJ, Kim JH, Kim KA, Woo JS, Lee JH: Acinic cell carcinoma of the head and neck: radiologic-pathologic correlation. J Comput Assist Tomogr; 2005 Jan-Feb;29(1):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the head and neck: radiologic-pathologic correlation.
  • OBJECTIVE: To describe and correlate the imaging and pathologic findings of acinic cell carcinoma (ACC) in the head and neck.
  • A parapharyngeal lesion was cystic mass with mural nodule, and a submandibular and a palate tumor were cystic lesions on CT.
  • [MeSH-major] Carcinoma, Acinar Cell / radiography. Head and Neck Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Child, Preschool. Diagnosis, Differential. Female. Hemorrhage / pathology. Hemorrhage / radiography. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Necrosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Palatal Neoplasms / pathology. Palatal Neoplasms / radiography. Parotid Neoplasms / pathology. Parotid Neoplasms / radiography. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiography. Retrospective Studies. Submandibular Gland Neoplasms / pathology. Submandibular Gland Neoplasms / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665697.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, Shah JP, Wong RJ, Ghossein RA, Lee NY: Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer; 2009 May 15;115(10):2128-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland.
  • BACKGROUND: To the authors' knowledge, the indications for adjuvant treatment in acinic cell carcinoma (AciCC) of the parotid gland have not been elucidated to date.
  • If high-grade tumors were defined on the basis of high mitotic activity (>2 mitoses/10 HPF) and/or tumor necrosis, high-grade carcinomas had a significantly lower DFS and OS (P = .001).
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Facial Nerve Injuries / etiology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309749.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Benkoël L, Bernard JP, Payan-Defais MJ, Crescence L, Franceschi C, Delmas M, Ouaissi M, Sastre B, Sahel J, Benoliel AM, Bongrand P, Silvy F, Gauthier L, Romagné F, Lombardo D, Mas E: Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues. Mol Cancer Ther; 2009 Feb;8(2):282-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues.
  • We have shown that the 16D10 antigen located on the mucin-like COOH-terminal domain of the feto-acinar pancreatic protein (FAPP) is expressed at the surface of human pancreatic tumor cell lines such as SOJ-6 cell line.
  • Furthermore, an in vivo study indicates that targeting this cell-membrane glycopeptide by the use of the monoclonal antibody (mAb) 16D10 inhibits the growth of SOJ-6 xenografts in nude mice.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Lipase / chemistry. Lipase / immunology. Pancreatic Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Antibody Specificity. Antigens, Neoplasm / immunology. Electrophoresis, Polyacrylamide Gel. Female. Fluorescence. Frozen Sections. Humans. Immunohistochemistry. Male. Microscopy, Confocal. Middle Aged. Neoplasm Metastasis. Organ Specificity. Preoperative Care. Protein Structure, Tertiary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190122.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; EC 3.1.1.3 / CEL protein, human; EC 3.1.1.3 / Lipase
  •  go-up   go-down


34. Triantafillidou K, Iordanidis F, Psomaderis K, Kalimeras E: Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study. J Oral Maxillofac Surg; 2010 Oct;68(10):2489-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study.
  • PURPOSE: Acinic cell carcinoma is a rare malignant tumor of salivary glands.
  • The purpose of this study is to evaluate the clinical outcome of acinic cell carcinoma in a group of 11 patients, who were treated in our clinic, and to discuss the management as well as the immunohistochemical features and prognosis of this carcinoma.
  • MATERIALS AND METHODS: The study included 11 patients with acinic cell carcinoma of the minor salivary glands who were treated in our clinic.
  • CONCLUSIONS: Acinic cell carcinoma is a rare malignant tumor of the salivary glands, characterized by an indolent clinical course with the potential for both local recurrence and distant metastases.
  • The immunohistochemical analysis of proliferation markers provides additional prognostic information for this tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis


35. Susani M, Kenner L, Culig Z: [Diagnostic of prostate cancer: conventional and molecular or cell biological methods]. Pathologe; 2009 Dec;30 Suppl 2:154-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic of prostate cancer: conventional and molecular or cell biological methods].
  • In over 95% of cases an acinar "usual" form of prostate cancer is diagnosed but can be very different in characteristics and differentiation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Prostate / pathology. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Humans. Interleukin-6 / genetics. Male. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prostate-Specific Antigen / analysis. Proto-Oncogene Proteins c-ets / analysis. Proto-Oncogene Proteins c-ets / genetics. Signal Transduction / genetics. Suppressor of Cytokine Signaling Proteins / analysis. Suppressor of Cytokine Signaling Proteins / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19802609.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Proto-Oncogene Proteins c-ets; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 20
  •  go-up   go-down


36. Ou SH, Ziogas A, Zell JA: Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol; 2010 Apr;5(4):420-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The presence of signet-ring cell component has been described as a prominent feature of EML4-ALK positive non-small cell lung cancer.
  • Patients with primary SRC of the lung were significantly younger than patients with adenocarcinoma, with a significantly higher proportion of poorly differentiated tumor and stage IV disease.
  • CONCLUSIONS: Primary SRC of the lung is a rare subtype of adenocarcinoma, carries a worse prognosis when compared to adenocarcinoma and shares many of the recently identified clinicopathologic characteristics ascribed to EML4-ALK positive non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / epidemiology. Adenocarcinoma, Papillary / epidemiology. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Signet Ring Cell / epidemiology. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130484.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-54404
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


37. Guzzo M, Ferrari A, Marcon I, Collini P, Gandola L, Pizzi N, Casanova M, Mattavelli F, Scaramellini G: Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan. Pediatr Blood Cancer; 2006 Nov;47(6):806-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan.
  • These results are presented in conjunction with a literature review of salivary tumors with a view to providing an up-to-date overview of the clinical course, prognosis, and treatment options for this rare tumor.
  • PROCEDURE: Fifty-two cases of epithelial salivary tumors were reviewed and the clinical-pathological information concerning tumor characteristics, therapy, and follow-up were collected.
  • RESULTS: The major salivary glands were the main site of tumor occurrence (79% of cases arose in parotid glands); 37 patients had benign tumors (pleomorphic adenoma), 15 had malignant tumors (12 mucoepidermoid carcinoma, 9 low grade).
  • When tumor enucleation was performed, recurrences occurred in 50% of benign neoplasms.
  • At the time of the report, all patients with benign tumors were alive, 35(95%) without evidence of disease; only one patient with malignant tumor died of disease.
  • CONCLUSIONS: Epithelial salivary glands tumor in children had different characteristics compared with their adult counterpart with respect to the frequency of histotypes and site of occurrence, but their prognosis seems to be similar.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Carcinoma, Acinar Cell / surgery. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Neoplasm Recurrence, Local / surgery. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16425245.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Hartzell HC, Yu K, Xiao Q, Chien LT, Qu Z: Anoctamin/TMEM16 family members are Ca2+-activated Cl- channels. J Physiol; 2009 May 15;587(Pt 10):2127-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ca(2+)-activated Cl- channels (CaCCs) perform many important functions in cell physiology including secretion of fluids from acinar cells of secretory glands, amplification of olfactory transduction, regulation of cardiac and neuronal excitability, mediation of the fast block to polyspermy in amphibian oocytes, and regulation of vascular tone.

  • Genetics Home Reference. consumer health - ANO5 gene.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1986 Aug 1;233(4763):558-60 [2425436.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5063-7 [2440042.001]
  • [Cites] Pflugers Arch. 1988 Oct;412(6):641-6 [2850536.001]
  • [Cites] J Gen Physiol. 1990 May;95(5):773-89 [2163430.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Neuron. 1991 Apr;6(4):547-55 [1849722.001]
  • [Cites] J Neurophysiol. 1992 Dec;68(6):2042-50 [1283407.001]
  • [Cites] Am J Physiol. 1993 Apr;264(4 Pt 1):C977-85 [7682780.001]
  • [Cites] Pflugers Arch. 1993 Aug;424(3-4):231-7 [8414911.001]
  • [Cites] J Gen Physiol. 1994 Aug;104(2):357-73 [7807053.001]
  • [Cites] Yeast. 1994 Oct;10(10):1363-81 [7900426.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):31016-26 [8537359.001]
  • [Cites] J Physiol. 1995 Nov 1;488 ( Pt 3):689-99 [8576858.001]
  • [Cites] Circ Res. 1996 May;78(5):936-44 [8620614.001]
  • [Cites] Am J Physiol. 1996 Aug;271(2 Pt 1):G304-10 [8770046.001]
  • [Cites] J Gen Physiol. 1996 Jul;108(1):35-47 [8817383.001]
  • [Cites] J Physiol. 1997 Jan 15;498 ( Pt 2):381-96 [9032686.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):C161-6 [9458724.001]
  • [Cites] Prog Biophys Mol Biol. 1997;68(1):69-119 [9481145.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 1):C161-75 [9886932.001]
  • [Cites] Int J Mol Med. 2005 Feb;15(2):353-8 [15647853.001]
  • [Cites] J Physiol. 2005 Jan 15;562(Pt 2):477-91 [15564283.001]
  • [Cites] J Biol Chem. 2009 Oct 23;284(43):29405-12 [17003041.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 1):E969-76 [7491950.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):H1732-44 [10564126.001]
  • [Cites] J Gen Physiol. 2000 Jan;115(1):59-80 [10613919.001]
  • [Cites] Mol Gen Genet. 1999 Dec;262(4-5):683-702 [10628851.001]
  • [Cites] Science. 2000 Oct 13;290(5490):341-4 [11030653.001]
  • [Cites] Pflugers Arch. 2001 May;442(2):273-9 [11417225.001]
  • [Cites] Eukaryot Cell. 2002 Aug;1(4):606-12 [12456008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903 [12477932.001]
  • [Cites] J Physiol. 2003 Feb 15;547(Pt 1):181-96 [12562904.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 14;302(3):534-8 [12615067.001]
  • [Cites] Cell Cycle. 2003 May-Jun;2(3):174-6 [12734416.001]
  • [Cites] Prostate. 2005 Sep 1;64(4):387-400 [15761874.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(1):22-7 [16113407.001]
  • [Cites] Int J Mol Med. 2005 Nov;16(5):919-24 [16211264.001]
  • [Cites] Exp Physiol. 2006 Jan;91(1):141-7 [16219661.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1821-31 [16261155.001]
  • [Cites] J Gen Physiol. 2006 May;127(5):577-89 [16636205.001]
  • [Cites] J Gen Physiol. 2006 Jul;128(1):73-87 [16801382.001]
  • [Cites] J Gen Physiol. 2006 Sep;128(3):247-59 [16940553.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1058-69 [16906560.001]
  • [Cites] J Cell Physiol. 2007 Mar;210(3):831-42 [17111356.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1594-601 [17308099.001]
  • [Cites] Biochem Biophys Res Commun. 2007 May 25;357(1):126-32 [17418107.001]
  • [Cites] J Neurophysiol. 2007 Jul;98(1):86-95 [17460105.001]
  • [Cites] Eukaryot Cell. 2005 Feb;4(2):281-8 [15701790.001]
  • [Cites] Annu Rev Physiol. 2005;67:719-58 [15709976.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):1099-106 [15882990.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):613-22 [15911878.001]
  • [Cites] Physiol Rev. 2005 Jul;85(3):1061-92 [15987802.001]
  • [Cites] Physiol Rev. 2008 Apr;88(2):639-72 [18391176.001]
  • [Cites] Curr Opin Neurobiol. 2008 Feb;18(1):60-8 [18508259.001]
  • [Cites] Exp Biol Med (Maywood). 2008 Jul;233(7):779-91 [18445774.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H97-H104 [18441200.001]
  • [Cites] J Gastroenterol. 2008;43(7):531-7 [18648740.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6306-12 [18676855.001]
  • [Cites] Dev Biol. 2008 Sep 1;321(1):141-9 [18585372.001]
  • [Cites] Dev Dyn. 2008 Sep;237(9):2566-74 [18729231.001]
  • [Cites] Channels (Austin). 2008 Jul-Aug;2(4):252-60 [18769137.001]
  • [Cites] Cell. 2008 Sep 19;134(6):1019-29 [18805094.001]
  • [Cites] Circ Res. 2008 Oct 10;103(8):864-72 [18776041.001]
  • [Cites] Science. 2008 Oct 24;322(5901):590-4 [18772398.001]
  • [Cites] Nature. 2008 Oct 30;455(7217):1210-5 [18724360.001]
  • [Cites] J Cell Biol. 2002 Jan 7;156(1):75-85 [11781335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):4008-13 [11904445.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):503-68 [11917096.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11369-74 [12172009.001]
  • [Cites] Pflugers Arch. 2007 Sep;454(6):879-89 [17361457.001]
  • [Cites] J Gen Physiol. 2007 Nov;130(5):513-24 [17968025.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):210-8 [18223323.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):758-68 [18083779.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1611-3 [18339837.001]
  • [Cites] J Mol Evol. 1995 Nov;41(5):675-9 [18345592.001]
  • [Cites] Anticancer Res. 2008 Jan-Feb;28(1A):75-83 [18383827.001]
  • [Cites] Int J Oncol. 2003 Jun;22(6):1375-81 [12739008.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Aug;285(2):F326-35 [12724129.001]
  • [Cites] Curr Opin Neurobiol. 2003 Aug;13(4):469-75 [12965295.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41114-25 [12907679.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49563-72 [12939260.001]
  • [Cites] J Neurophysiol. 2003 Dec;90(6):3764-73 [12944538.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3059-64 [14981236.001]
  • [Cites] Mol Biol Evol. 2004 Mar;21(3):587-98 [14694080.001]
  • [Cites] Curr Biol. 2004 Mar 9;14(5):406-11 [15028216.001]
  • [Cites] J Gen Physiol. 2004 Apr;123(4):323-5 [15051804.001]
  • [Cites] J Gen Physiol. 2004 Apr;123(4):327-40 [15051805.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1255-61 [15124103.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22461-8 [15010458.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):107-13 [15215166.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1982 Jul 22;215(1201):491-7 [6127718.001]
  • [Cites] J Physiol. 1982 Oct;331:253-84 [7153904.001]
  • [Cites] J Physiol. 1983 Sep;342:309-25 [6313909.001]
  • (PMID = 19015192.001).
  • [ISSN] 1469-7793
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060448-08; United States / NIGMS NIH HHS / GM / GM060448-08; United States / NEI NIH HHS / EY / EY014852-08; United States / NEI NIH HHS / EY / R01 EY014852-08; United States / NIGMS NIH HHS / GM / R01 GM060448; United States / NEI NIH HHS / EY / R01 EY014852; United States / NIGMS NIH HHS / GM / GM60448; United States / NEI NIH HHS / EY / EY014852
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ANO1 protein, human; 0 / Chloride Channels; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 94
  • [Other-IDs] NLM/ PMC2697287
  •  go-up   go-down


39. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM: Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia; 2008 Aug;10(8):782-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic evaluation revealed a chronic pancreatitis-like state characterized by acinar-to-ductal metaplasia and a well-vascularized fibroinflammatory stroma that develops by 3 months.
  • Increased proliferation, cellular atypia, and loss of normal cell/tissue organization are typical features in transgenic pancreata.
  • However, cell lines derived from spontaneous lesions are aggressively tumorigenic when injected into syngeneic or nude mice.
  • The progressive nature of the metaplastic/dysplastic changes observed in this model make it a valuable tool for examining the transition from chronic inflammation to neoplasia.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2007 Nov;9(11):979-86 [18030366.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Am J Clin Oncol. 2007 Oct;30(5):526-30 [17921715.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):139-46 [10657949.001]
  • [Cites] Genes Dev. 2000 Sep 1;14(17):2123-33 [10970876.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Jul;226(7):692-700 [11444106.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1403-4 [12045253.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):41-8 [15671526.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):575-84 [15681840.001]
  • [Cites] Cell Res. 2005 Jan;15(1):72-7 [15686632.001]
  • [Cites] Pancreas. 2005 Mar;30(2):148-57 [15714137.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):817-23 [15609315.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1808-13 [15753378.001]
  • [Cites] Gut. 2005 Apr;54(4):510-4 [15753536.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jun;55(6):559-64 [15726370.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1217-24 [15477758.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):436-9 [15982220.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1157-64 [15920540.001]
  • [Cites] Gut. 2005 Oct;54(10):1461-7 [15870229.001]
  • [Cites] JAMA. 2005 Dec 14;294(22):2872-8 [16352795.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1943-51 [16373709.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):583-90 [16034525.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2165-78 [16762637.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):437-45 [16820089.001]
  • [Cites] ChemMedChem. 2006 Jun;1(6):603-10 [16892400.001]
  • [Cites] JOP. 2006;7(5):465-72 [16998243.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1265-70 [16979953.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3240-7 [17172427.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1856-69 [17123526.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):2012-5 [17123529.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):50-9 [17200706.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • [Cites] Pancreatology. 2001;1(4):363-8 [12120215.001]
  • [Cites] Pancreas. 2002 Jul;25(1):26-30 [12131767.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):455-63 [12189387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12483-8 [12221288.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] Nat Rev Drug Discov. 2003 Nov;2(11):879-90 [14668809.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3127-38 [14681205.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Pancreas. 2004 Jan;28(1):58-64 [14707731.001]
  • [Cites] Pancreatology. 2003;3(6):487-96 [14673200.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1235-40 [14977820.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71 [15166955.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Pancreas. 2004 Oct;29(3):179-87 [15367883.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1121-35 [1693546.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1137-46 [2350785.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):559-68 [1372155.001]
  • [Cites] Differentiation. 1994 Nov;58(1):53-64 [7532601.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Microsc Res Tech. 1997 Jun 1-15;37(5-6):509-19 [9220428.001]
  • [Cites] Cancer J Sci Am. 1998 May-Jun;4(3):194-203 [9612602.001]
  • [Cites] Biotechniques. 1998 Jun;24(6):922-4, 926, 928 [9631181.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):317-24 [10069471.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):1223-9 [10233860.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:219-30 [10415867.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):194-202 [15644546.001]
  • [Cites] Annu Rev Physiol. 2007;69:249-69 [17059357.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Histol Histopathol. 2007 Jun;22(6):661-76 [17357096.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S113-31 [17486047.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] J Leukoc Biol. 2007 Aug;82(2):204-12 [17513693.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]
  • [Cites] Pancreas. 2007 Oct;35(3):212-7 [17895840.001]
  • (PMID = 18670639.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122815; United States / NCI NIH HHS / CA / R25 CA057730; United States / NIEHS NIH HHS / ES / T32 ES07247; United States / NCI NIH HHS / CA / R21 CA122815; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NIEHS NIH HHS / ES / ES07784; United States / NIEHS NIH HHS / ES / T32 ES007247; United States / NCI NIH HHS / CA / R25CA57730; United States / NCI NIH HHS / CA / CA105345; United States / NCI NIH HHS / CA / U01 CA105345
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pyrazoles; 0 / Sulfonamides; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2481568
  •  go-up   go-down


40. Kaifi JT, Heidtmann S, Schurr PG, Reichelt U, Mann O, Yekebas EF, Wachowiak R, Strate T, Schachner M, Izbicki JR: Absence of L1 in pancreatic masses distinguishes adenocarcinomas from poorly differentiated neuroendocrine carcinomas. Anticancer Res; 2006 Mar-Apr;26(2A):1167-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatic adenocarcinoma is a tumor with fatal outcome.
  • Cell adhesion molecules, such as L1 (CD171), have an essential function in tumor progression.
  • No expression was found in acinar or ductal cells of normal pancreatic tissue.
  • Since L1 was previously found to be expressed specifically in neuroendocrine pancreatic carcinomas, its absence in unclear pancreatic masses might hint at a ductal origin for a malignant pancreatic tumor.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / immunology. Carcinoma, Neuroendocrine / pathology. Leukocyte L1 Antigen Complex / biosynthesis. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619519.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


41. Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, Kondo T, Oshita F, Ito H, Tsuboi M, Nakayama H, Kameda Y, Noda K, Yamada K: Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer; 2010 Sep;69(3):361-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small-cell lung cancer.
  • The clinicopathological features of EML4-ALK-positive adenocarcinoma are reported to include its high incidence in young, non-smoking patients, tumors that show distinct solid or acinar growth patterns with or without signet-ring cell histology, and its mutually exclusive occurrence with mutations in EGFR and KRAS.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Diagnosis, Differential. Female. Humans. Mutation / genetics. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. Time Factors. Tomography, X-Ray Computed. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20659620.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EML4-ALK fusion protein, human; 0 / KRAS protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


42. Alì G, Donati V, Loggini B, Servadio A, Dell'Omodarme M, Prati MC, Camacci T, Lucchi M, Melfi F, Mussi A, Fontanini G: Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol; 2008 Oct;39(10):1465-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, estrogen receptor beta expression was low or negative in 68.2% of solid subtypes, whereas it was high in 76.5% of nonmucinous bronchioloalveolar, in 69.4% of acinar, and in 61.2% of papillary patterns (P = .00004).
  • Furthermore, a strong association between estrogen receptor beta expression and tumor histologic grade was observed: estrogen receptor beta was highly expressed predominantly in well- and moderately differentiated tumors (P = .0014).
  • [MeSH-major] Adenocarcinoma / metabolism. Estrogen Receptor beta / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Dedifferentiation. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymph Nodes / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620727.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta
  •  go-up   go-down


43. Wesson RN, Sparaco A, Smith MD: Chronic pancreatitis in a patient with malnutrition due to anorexia nervosa. JOP; 2008;9(3):327-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been demonstrated that protein energy malnutrition is associated with increased levels of proinflammatory cytokines as well as pancreatic acinar cell damage and ductal disruption.
  • Our patient underwent surgery based on the presumption that she had a symptomatic cystic neoplasm.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469448.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


44. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM: DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med; 2009 May 26;6(5):e1000068
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
  • Here we report the discovery of DEAR1 (ductal epithelium-associated RING Chromosome 1), a novel gene encoding a member of the TRIM (tripartite motif) subfamily of RING finger proteins, and provide evidence for its role as a dominant regulator of acinar morphogenesis in the mammary gland and as an independent predictor of local recurrence-free survival in early-onset breast cancer.
  • DEAR1 missense mutations and homozygous deletion (HD) were discovered in breast cancer cell lines and tumor samples.
  • Introduction of the DEAR1 wild type and not the missense mutant alleles to complement a mutation in a breast cancer cell line, derived from a 36-year-old female with invasive breast cancer, initiated acinar morphogenesis in three-dimensional (3D) basement membrane culture and restored tissue architecture reminiscent of normal acinar structures in the mammary gland in vivo.
  • Stable knockdown of DEAR1 in immortalized human mammary epithelial cells (HMECs) recapitulated the growth in 3D culture of breast cancer cell lines containing mutated DEAR1, in that shDEAR1 clones demonstrated disruption of tissue architecture, loss of apical basal polarity, diffuse apoptosis, and failure of lumen formation.
  • CONCLUSIONS: Our data provide compelling evidence for the genetic alteration and loss of expression of DEAR1 in breast cancer, for the functional role of DEAR1 in the dominant regulation of acinar morphogenesis in 3D culture, and for the potential utility of an immunohistochemical assay for DEAR1 expression as an independent prognostic marker for stratification of early-onset disease.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jun 20;417(6891):871-5 [12075357.001]
  • [Cites] Cell. 2008 Nov 28;135(5):865-78 [19041750.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):521-6 [12522268.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] J Cell Biol. 2004 Feb 16;164(4):603-12 [14769856.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2358-62 [14630830.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1264-74 [15316900.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):985-90 [3657865.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7351-7 [1977518.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):48-58 [2487147.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):997-1003 [2033434.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):327-31 [1677695.001]
  • [Cites] Dev Biol. 1991 Nov;148(1):107-16 [1936552.001]
  • [Cites] EMBO J. 1992 Feb;11(2):629-42 [1311253.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1468-74 [10188892.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2182-9 [10232606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] Trends Biochem Sci. 1992 Sep;17(9):344-5 [1412709.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5305-10 [1437549.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10877-81 [1438292.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Nov;5(4):311-20 [1283319.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Ann N Y Acad Sci. 1993 Jun 11;684:174-92 [8317827.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3383-7 [8159756.001]
  • [Cites] N Engl J Med. 1994 Jun 2;330(22):1580-8 [8177249.001]
  • [Cites] Semin Cancer Biol. 1994 Apr;5(2):157-65 [8061331.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] EMBO J. 1995 May 1;14(9):2020-33 [7744009.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):138-44 [7622286.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):19-27 [7666458.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Cell. 1997 Aug 22;90(4):797-807 [9288758.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):25-31 [9288094.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):285-91 [9354791.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3533-7 [9721855.001]
  • [Cites] Cancer J Sci Am. 1998 Sep-Oct;4(5):302-7 [9815294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 [9843973.001]
  • [Cites] Biochem Cell Biol. 1998;76(2-3):351-8 [9923704.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):298-301 [10888877.001]
  • [Cites] Hum Mol Genet. 2000 Oct 12;9(17):2553-62 [11030761.001]
  • [Cites] EMBO J. 2001 May 1;20(9):2140-51 [11331580.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Lancet. 2002 Apr 27;359(9316):1471-7 [11988246.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):354-61 [10398429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9176-81 [15967981.001]
  • [Cites] Cell. 2006 Aug 11;126(3):489-502 [16901783.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1235-45 [17060907.001]
  • [Cites] Cell. 2007 Feb 9;128(3):459-75 [17289567.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 31;360(3):531-8 [17624313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):35-42 [17855007.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • (PMID = 19536326.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / F32 CA090036-01A1; United States / NCI NIH HHS / CA / F32 CA090036-02; United States / NCI NIH HHS / CA / CA090036-01A1; United States / NCI NIH HHS / CA / T32CA09299; United States / NCI NIH HHS / CA / CA090036-02; United States / NCI NIH HHS / CA / T32 CA009299; United States / NCI NIH HHS / CA / F32 CA090036
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Proteins; EC 6.3.2.19 / TRIM62 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2673042
  •  go-up   go-down


45. Wang Y, Xie SL, Wang CF, Liu SM, Shan Y, Zhao DB, Liu Q, Luo W, Zhao P: [Clinical and pathological analysis of 114 cases with non-ductal pancreatic adenocarcinoma occupying lesions]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1089-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (4) pancreaticoduodenectomy was performed in 26 patients, distal pancreatectomy in 53, tumor enucleation in 15, segmental pancreatectomy in 9, partial resection in 3, duodenum-preserving pancreatic head resection in 1 and palliative surgery (either cholecystojejunostomy anastomosis or gastrojejunostomy) in 7;.
  • (5) pathologic analysis revealed 35 solid pseudopapillary neoplasm of pancreas, 28 pancreatic endocrine tumors, 18 focal chronic pancreatitis, 11 serous cystic neoplasms, 9 mucinous cystic neoplasms, 4 pancreatic cysts, 3 acinar cell carcinomas, 2 pancreatic cavernous hemangiomas, 1 sarcoma of pancreas, 1 sarcomatoid carcinoma of pancreas, 1 pancreatic schwannoma and 1 pancreatic neuroblastoma.
  • CONCLUSION: The non-ductal pancreatic adenocarcinoma-occupying lesions have no specific clinical presentation or serum tumor marker.
  • [MeSH-major] Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. CA-19-9 Antigen / metabolism. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646423.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


46. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Ten acinar adenocarcinomas of varying grades were also immunostained as controls.
  • Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


47. Mocan S, Stolnicu S, Rădulescu D, Petrovan C: [Acinic cell adenocarcinoma of the lip]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell adenocarcinoma of the lip].
  • [Transliterated title] Adenocarcinom cu celule acinare cu localizare la nivelul buzei. Prezentare de caz.
  • The variable histological appearance of acinic cell carcinoma coupled with its uncommon occurrence account for considerable diagnostic difficulties.
  • The tumour mass was excised, fixed in formaline, embedded in paraffin and the sections were stained with Haematoxylin-Eosin, PAS-Haematoxylin, PAS-Alcian blue and Perls.
  • The tumour was nodular, well circumscribed, with a cystic appearance on the cut surface.
  • Microscopically, the tumour had a papillary-cystic growth, with one large cystic space lined by epithelium of variable thickness and branching projections of epithelium occupying a large portion of the cyst's lumen.
  • Different cellular features were recognised in the tumour, with the presence of both serous and mucous acinar differentiation.
  • Acinic cell adenocarcinoma is a malignant epithelial neoplasm in which the neoplastic cells demonstrate not only serous acinar differentiation.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607848.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


48. Negahban S, Daneshbod Y, Khademi B, Seif I: Papillary cystic acinic cell carcinoma with many psammoma bodies, so-called psammoma body-rich papillary cystic acinic cell carcinoma: report of a case with fine needle aspiration findings. Acta Cytol; 2009 Jul-Aug;53(4):440-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary cystic acinic cell carcinoma with many psammoma bodies, so-called psammoma body-rich papillary cystic acinic cell carcinoma: report of a case with fine needle aspiration findings.
  • We present a case of papillary cystic acinic cell carcinoma with many psammoma bodies and discuss the diagnostic pitfalls with other salivary gland tumors.
  • A preliminary diagnosis of papillary cystic salivary gland neoplasm was made and supeficial parotidectomy performed.
  • A diagnosis of papillary cystic acinic cell carcinoma with many psammoma bodies was made.
  • Aspiration cytology of papillary cystic acinic cell carcinoma with many psammoma bodies can be confused with more common tumors, such as cystic mixed tumor and adenoid cystic carcinoma with cannonballs, low grade mucoepidermoid carcinoma or cystic papillary carcinoma of the thyroid.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697733.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Spencer ML, Neto AG, Fuller GN, Luna MA: Intracranial extension of acinic cell carcinoma of the parotid gland. Arch Pathol Lab Med; 2005 Jun;129(6):780-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial extension of acinic cell carcinoma of the parotid gland.
  • We report the case of a 47-year-old woman who experienced multiple recurrences of acinic cell carcinoma, lung metastasis, and intracranial extension of the tumor during a 32-year period.
  • In this report, the clinical, microscopic, histochemical, and electron microscopy features of this acinic cell carcinoma are described, and a review of published information about this neoplasm is presented.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Neoplasm Recurrence, Local / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Cytoplasm / ultrastructure. Cytoplasmic Granules / chemistry. Cytoplasmic Granules / ultrastructure. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Periodic Acid-Schiff Reaction

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913428.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R: Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. Int J Immunopathol Pharmacol; 2009 Jul-Sep;22(3):755-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer.
  • High expression of prostate stem cell antigen (PSCA) has been shown to be associated with adverse prognostic features in clinically-diagnosed prostate cancer.
  • PSCA expression was evaluated immunohistochemically in normal-looking epithelium (NEp), high-grade prostatic intraepithelial neoplasia (HGPIN) and pT2a Gleason score 6 acinar adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Carcinoma, Acinar Cell / immunology. Immunohistochemistry. Incidental Findings. Membrane Glycoproteins / analysis. Neoplasm Proteins / analysis. Prostatic Intraepithelial Neoplasia / immunology. Prostatic Neoplasms / immunology. Urinary Bladder Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm. Cell Transformation, Neoplastic / immunology. GPI-Linked Proteins. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Prostatectomy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822092.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / GPI-Linked Proteins; 0 / Ki-67 Antigen; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human
  •  go-up   go-down


51. Begnami MD, Quezado M, Pinto P, Linehan WM, Merino M: Adenoid cystic/basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med; 2007 Apr;131(4):637-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate: review and update.
  • CONTEXT: Although most prostate carcinomas are of the conventional acinar type, unusual variants have been reported.
  • Adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are only a few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • OBJECTIVE: To review current literature together with the clinical, pathologic, and immunohistochemical features of adenoid cystic/basal cell carcinoma of the prostate and offer a practical approach to the diagnosis--including the differential diagnosis--of this neoplasm in surgical pathologic specimens.
  • DATA SOURCES: Adenoid cystic/basal cell carcinoma of the prostate is composed of infiltrating basaloid cells forming dilated acinar and cribriform spaces with luminal basementlike material.
  • Differentiation of adenoid cystic/basal cell carcinoma from basal cell hyperplasia and cribriform pattern of acinar adenocarcinoma may be difficult.
  • CONCLUSIONS: Various histologic and immunohistochemical features are helpful in recognizing adenoid cystic/basal cell carcinoma of the prostate.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology


52. Neto AG, Pineda-Daboin K, Spencer ML, Luna MA: Sinonasal acinic cell carcinoma: a clinicopathologic study of four cases. Head Neck; 2005 Jul;27(7):603-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal acinic cell carcinoma: a clinicopathologic study of four cases.
  • BACKGROUND: Acinic cell carcinoma is a low-grade malignant epithelial salivary gland neoplasm with a predilection for the parotid gland.
  • To date, only 11 cases of sinonasal acinic cell carcinomas have been reported in the English-language literature.
  • We present the clinicopathologic features of four sinonasal acinic cell carcinomas.
  • METHODS: The demographic data and pathologic material of four patients with sinonasal acinic cell carcinoma identified from the files of the Department of Pathology at The University of Texas M. D.
  • CONCLUSIONS: Sinonasal acinic cell carcinoma is a distinct low-grade carcinoma that can be distinguished from other neoplasms by light microscopy and histochemical staining methods.
  • Pathologists and surgeons should be aware of the occurrence of this type of salivary gland neoplasm in the sinonasal tract.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Microscopy, Electron. Middle Aged. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900565.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


53. Tonini G, Rosini R, Teppa A, Aulenti V, Kalantary F, Tosana M, Bianchi D, Zorzi F: [Adenoid cystic/basal cell carcinoma of the prostate:case report]. Urologia; 2008 Oct-Dec;75(4):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic/basal cell carcinoma of the prostate:case report].
  • Although most prostate carcinomas belong to the conventional acinar type, unusual variants have been reported.
  • The adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are quite few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • METHODS. A 71-year-old man had an increased PSA value (5.11 ng/dL); the prostatic biopsy examination was positive for adenoid cystic/basal cell carcinoma.
  • The histology examination showed an acinar conventional carcinoma and adenoid cystic/basal cell carcinoma.
  • CONCLUSIONS. Various histologic and immunohistochemical features are helpful in recognizing the adenoid cystic/basal cell carcinoma of the prostate.
  • This tumor has a biological potential that can result in metastases in some cases; the current treatment consists primarily in the surgical resection.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086341.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


54. Tanahashi C, Yabuki S, Akamine N, Yatabe Y, Ichihara S: Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman. Pathol Int; 2007 Jan;57(1):43-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman.
  • Acinic cell carcinoma of the breast is an uncommon neoplasm.
  • Reported herein is the first case of primary acinic cell carcinoma of the breast in a Japanese woman.
  • To the naked eye, the tumor appeared well circumscribed and the cut surface was grayish-pink and hemorrhaging.
  • Microscopically, the tumor was predominantly made up of a monotonous proliferation of cells with a finely granular cytoplasm, resembling acinic cells of the parotid gland.
  • In spite of extensive sampling, no common histological patterns of breast carcinoma such as in situ and invasive ductal carcinoma were recognized in the present case, indicating that the present case was pure acinic cell carcinoma.
  • In addition, the immunohistochemical profile of this tumor was identical to that of the acinic cell carcinoma of the salivary gland: estrogen receptor, progesterone receptor, HER2 and cytokeratin (CK)20 were negative and amylase and CK7 were positive.
  • The patient has been well for 22 months since the wide local excision of the tumor and no signs of salivary neoplasm are evident to date.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology


55. Tarasova MV, Pozharisskiĭ KM, Ten VP, Arzumanov AA, Kudaĭbergenova AG: [The proliferative properties and regulators of the mitotic cell cycle of prostate adenocarcinoma]. Arkh Patol; 2009 Nov-Dec;71(6):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The proliferative properties and regulators of the mitotic cell cycle of prostate adenocarcinoma].
  • The authors have made an immunohistochemical determination of Ki-67, topoisomerase IIalpha, cyclins D1, A, and B1, and calculated their indices in 145 acinar adenocarcinomas of the prostate.
  • This tumor is characterized by a wide range of Ki-67 index (from 3 to 90% or more) although 90% of cases are in the range of 5-35%.
  • The exception is cyclin D1 that shows high expression in intact and tumor tissues, which is frequently greater than that of Ki-67, and its stable expression independent of the Gleason score.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131501.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


56. Baumgartner M, Radziwill G, Lorger M, Weiss A, Moelling K: c-Src-mediated epithelial cell migration and invasion regulated by PDZ binding site. Mol Cell Biol; 2008 Jan;28(2):642-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Src-mediated epithelial cell migration and invasion regulated by PDZ binding site.
  • c-Src tyrosine kinase controls proliferation, cell adhesion, and cell migration and is highly regulated.
  • The intact GENL sequence maintained c-Src in an inactive state in starved cells and restricted c-Src functions that might lead to metastatic transformation under normal growth conditions. c-Src with a C-terminal Leu/Ala mutation in GENL (Src-A) promoted the activation and translocation of cortactin and focal adhesion kinase and increased the motility and persistence of cell migration on the basement membrane.
  • Src-A promoted increased extracellular proteolytic activity, and in acinar cultures, it led to the escape of cells through the basement membrane into the surrounding matrix.
  • We ascribe the regulatory function of C-terminal Leu to the role of GENL in modulating c-Src activity downstream of cell matrix adhesion.
  • [MeSH-major] Cell Movement. Epithelial Cells / cytology. Epithelial Cells / metabolism. PDZ Domains. Proto-Oncogene Proteins pp60(c-src) / chemistry. Proto-Oncogene Proteins pp60(c-src) / metabolism
  • [MeSH-minor] Binding Sites. Bone Marrow Cells / cytology. Bone Marrow Cells / enzymology. Cadherins / metabolism. Cell Adhesion. Cell Line. Cell Polarity. Cell Shape. Cell Transformation, Neoplastic. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Gene Expression Regulation, Enzymologic. Humans. Ligands. Neoplasm Invasiveness. Phosphorylation. Wound Healing

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1591-5 [9430700.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13911-5 [9153252.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1235-44 [10087266.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7918-27 [15489910.001]
  • [Cites] EMBO J. 1999 Jun 1;18(11):3013-23 [10357814.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):769-81 [15557125.001]
  • [Cites] J Cell Sci. 2005 Jan 1;118(Pt 1):79-87 [15585574.001]
  • [Cites] J Cell Sci. 2005 Jan 1;118(Pt 1):51-63 [15585576.001]
  • [Cites] Structure. 2005 Jun;13(6):861-71 [15939018.001]
  • [Cites] Dev Cell. 2005 Aug;9(2):185-96 [16054026.001]
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):342-52 [15963732.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):542-7 [16099634.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):8-19 [16170364.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3034-43 [16540652.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):8183-9 [16439366.001]
  • [Cites] Exp Cell Res. 2006 May 1;312(8):1240-53 [16442522.001]
  • [Cites] J Cell Physiol. 2006 Jul;208(1):141-8 [16607610.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4399-409 [16738308.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):20851-64 [16728403.001]
  • [Cites] J Cell Sci. 2006 Aug 15;119(Pt 16):3385-98 [16882694.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):541-8 [16905303.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):516-23 [16919435.001]
  • [Cites] Physiology (Bethesda). 2006 Oct;21:352-61 [16990456.001]
  • [Cites] EMBO J. 2007 Jun 6;26(11):2633-44 [17491594.001]
  • [Cites] Cells Tissues Organs. 2005;179(1-2):73-80 [15942195.001]
  • [Cites] J Cell Sci. 2005 Jun 15;118(Pt 12):2613-23 [15914540.001]
  • [Cites] Curr Biol. 2005 Jul 26;15(14):1276-85 [16051170.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):8176-82 [10713141.001]
  • [Cites] J Mol Med (Berl). 2000;78(7):380-8 [11043381.001]
  • [Cites] Biochemistry. 2001 Feb 20;40(7):2004-10 [11329267.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jun;2(6):467-75 [11389470.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 16):2967-76 [11686300.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):531-7 [12094219.001]
  • [Cites] J Cell Biol. 2003 Mar 3;160(5):753-67 [12615911.001]
  • [Cites] J Cell Biol. 2003 Apr 14;161(1):197-209 [12695504.001]
  • [Cites] Sci STKE. 2003 Apr 22;2003(179):RE7 [12709532.001]
  • [Cites] Curr Biol. 2003 Aug 19;13(16):1442-50 [12932330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13298-302 [14593208.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):154-61 [14743221.001]
  • [Cites] FASEB J. 2004 Feb;18(2):364-6 [14688206.001]
  • [Cites] J Cell Biol. 2004 Feb 16;164(4):603-12 [14769856.001]
  • [Cites] J Cell Sci. 2004 Mar 1;117(Pt 7):989-98 [14996930.001]
  • [Cites] J Cell Biol. 2004 Apr 26;165(2):263-73 [15117969.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2794-803 [15075377.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5269-80 [15169891.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):77-102 [15246681.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):121-44 [15246683.001]
  • [Cites] Matrix Biol. 2004 May;23(2):75-85 [15246107.001]
  • [Cites] Trends Biochem Sci. 2004 Jun;29(6):285-9 [15276180.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):209-14 [15380511.001]
  • [Cites] J Cell Biol. 1993 Mar;120(6):1417-26 [7680654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5686-9 [8202549.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):539-44 [7566154.001]
  • [Cites] Mol Carcinog. 1998 Apr;21(4):261-72 [9585256.001]
  • (PMID = 18039857.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Ligands; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src)
  • [Other-IDs] NLM/ PMC2223407
  •  go-up   go-down


57. Smukalla K, Kalinski T, Motsch C: [Distant metastases on acinic cell carcinoma of the parotid gland after 12 years symptom-free interval]. Laryngorhinootologie; 2006 Aug;85(8):586-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distant metastases on acinic cell carcinoma of the parotid gland after 12 years symptom-free interval].
  • Acinic cell carcinoma of parotid gland as cause of distant metastases are rare.
  • The patient was a 60-year-old woman who had in 1993 a acinic cell carcinoma of right parotid gland.
  • Tumour can be resected through total parotidectomy with facial nerve anastomosis and modified radical neck dissection (T (3) N (2b) M (0)).
  • Since the operation the patient has remained symptom-free without any sign of tumour recurrence.
  • Histologically and immunohistochemically the diagnosis of distant metastase on acinic carcinoma of the parotid gland was confirmed.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Manubrium. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Female. Follow-Up Studies. Humans. Middle Aged. Neck Dissection. Neoplasm Staging. Osteolysis / diagnosis. Osteolysis / pathology. Osteolysis / surgery. Parotid Gland / pathology. Parotid Gland / surgery. Radionuclide Imaging. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883494.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Reske SN: [PET and PET-CT of malignant tumors of the exocrine pancreas]. Radiologe; 2009 Feb;49(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic acinar tumors are much rarer and originate from secretion-producing parenchymal cells of the pancreas.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Acinar Cell / radionuclide imaging. Carcinoma, Pancreatic Ductal / radionuclide imaging. Image Processing, Computer-Assisted. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Staging. Pancreas / pathology. Pancreas / radionuclide imaging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19219476.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 43
  •  go-up   go-down


59. Flores LG, Bertolini S, Yeh HH, Young D, Mukhopadhyay U, Pal A, Ying Y, Volgin A, Shavrin A, Soghomonyan S, Tong W, Bornmann W, Alauddin MM, Logsdon C, Gelovani JG: Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT. PLoS One; 2009 Nov 24;4(11):e7977
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [(18)F]FEDL is a novel radioligand of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), which is overexpressed in peritumoral pancreatic acinar cells.
  • CONCLUSION/SIGNIFICANCE: We have demonstrated the feasibility of detection of early pancreatic tumors by non-invasive imaging with [(18)F]FEDL PET/CT of tumor biomarker HIP/PAP over-expressed in peritumoral pancreatic tissue.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Lactose .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2003 May;124(5):1292-9 [12730869.001]
  • [Cites] Pancreatology. 2001;1(1):43-7 [12120267.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1441-50 [12890698.001]
  • [Cites] FEBS Lett. 1994 Jan 3;337(1):114-8 [8276102.001]
  • [Cites] J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40 [8784228.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Curr Opin Struct Biol. 1999 Oct;9(5):585-90 [10508765.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):779-87 [15791284.001]
  • [Cites] Biochim Biophys Acta. 2005 May 25;1723(1-3):8-18 [15715980.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5199-202 [16127752.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10613-22 [16288055.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Semin Nucl Med. 2006 Jul;36(3):248-56 [16762614.001]
  • [Cites] Hum Pathol. 2006 Aug;37(8):1066-75 [16867870.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):948-56 [17611392.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 May;35(5):990-8 [18057932.001]
  • [Cites] Pancreatology. 2008;8(2):110-25 [18382097.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4819-26 [18559529.001]
  • [Cites] Pancreas. 2009 Jul;38(5):527-33 [19342980.001]
  • [Cites] Mol Imaging Biol. 2011 Jun;13(3):536-46 [20593279.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1525-33 [10550309.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):409-16 [10667595.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):50-62 [10935470.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):243-8 [10962454.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] Dig Dis. 2001;19(1):76-84 [11385254.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1471-4 [11396234.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] Dig Dis Sci. 2003 Mar;48(3):459-64 [12757156.001]
  • (PMID = 19956730.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA126577; United States / NCI NIH HHS / CA / U24 CA126577-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Fluorine Radioisotopes; 0 / Lectins, C-Type; 0 / Ligands; 0 / O-galactopyranosyl-(1-4')-2'-deoxy-2'-fluoroethylglucopyranose; 0 / Radiopharmaceuticals; 0 / pancreatitis-associated protein; J2B2A4N98G / Lactose
  • [Other-IDs] NLM/ PMC2776527
  •  go-up   go-down


60. Hosoda W, Takagi T, Mizuno N, Shimizu Y, Sano T, Yamao K, Yatabe Y: Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol Int; 2010 May;60(5):358-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using immunostaining of CK7, CDX2, neuroendocrine markers and KRAS mutation analysis, we examined 57 FNA cell block sections and 61 surgically-resected specimens (25 invasive ductal carcinomas, 25 endocrine tumors, and 11 acinar cell tumors).
  • In the majority of the matched pairs, the diagnoses between EUS-FNA and surgical specimens were concordant using the following criteria: neuroendocrine markers negative, CK7 positive, and mutated KRAS gene for invasive ductal carcinomas; neuroendocrine markers diffusely positive, CK7 and CDX2 negative, and wild-type KRAS gene for well-differentiated endocrine tumors; and neuroendocrine markers no more than focal positive, CK7 and CDX2 with various staining patterns, and wild-type KRAS gene for acinar cell carcinomas.
  • Expression of CK7 and/or CDX2 in addition to KRAS mutations were occasionally seen in endocrine carcinomas, but not in well-differentiated endocrine tumors, suggesting that ductal differentiation in an endocrine tumor may be a predictor of aggressive disease.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Islet Cell / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Endosonography / methods. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. DNA Mutational Analysis. DNA, Neoplasm / analysis. Homeodomain Proteins / metabolism. Humans. Keratin-7 / metabolism. Pancreas / metabolism. Pancreas / pathology. Pancreatectomy. Prognosis. Prospective Studies. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. ras Proteins / genetics. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518885.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / KRAS protein, human; 0 / Keratin-7; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


61. Carlsson L, Lennartsson L, Ronquist G, Larsson A, Nilson S, Nilsson O: Mode of growth determines differential expression of prostasomes in cultures of prostate cancer cell lines and opens for studies of prostasome gene expression. Ups J Med Sci; 2006;111(3):293-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mode of growth determines differential expression of prostasomes in cultures of prostate cancer cell lines and opens for studies of prostasome gene expression.
  • The exocrine secretion of the acinar gland cells in the human prostate consists of, among other components, a serous secretion and prostasomes.
  • Therefore, we are trying to characterize prostasome antigens by analysing prostasome-producing cell lines of prostate cancers with the cDNA microarray technique.
  • We studied the expression of prostasomes in the cell lines PC3, DU145 and LNCaP.
  • [MeSH-major] Prostatic Neoplasms / genetics. Prostatic Neoplasms / secretion. Secretory Vesicles / genetics. Secretory Vesicles / secretion
  • [MeSH-minor] Animals. Cell Line, Tumor. Gene Expression. Humans. Male. Microscopy, Electron, Transmission. Neoplasm Transplantation. Oligonucleotide Array Sequence Analysis. Rats. Rats, Nude. Spheroids, Cellular. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578796.001).
  • [ISSN] 0300-9734
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


62. Furonaka O, Takeshima Y, Awaya H, Kushitani K, Kohno N, Inai K: Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int; 2005 Jun;55(6):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma.
  • The methylation status of the MGMT gene was investigated by methylation-specific polymerase chain reaction (PCR) and expression status was investigated by immunohistochemistry in 70 cases of pulmonary squamous cell carcinoma (pulmonary SqCC), including 23 cases of the central type and 47 cases of the peripheral type, and in 53 cases of the peripheral type of pulmonary adenocarcinoma (AC).
  • In AC with mixed subtypes showing MGMT methylation, the level of MGMT expression in the bronchioloalveolar carcinoma (BAC) area (non-invasive status) was significantly higher than that in the papillary or acinar AC area (invasive status; P = 0.0002).
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. DNA Methylation. Lung Neoplasms / pathology. O(6)-Methylguanine-DNA Methyltransferase / genetics
  • [MeSH-minor] DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943786.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


63. Deramaudt TB, Sachdeva MM, Wescott MP, Chen Y, Stoffers DA, Rustgi AK: The PDX1 homeodomain transcription factor negatively regulates the pancreatic ductal cell-specific keratin 19 promoter. J Biol Chem; 2006 Dec 15;281(50):38385-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The PDX1 homeodomain transcription factor negatively regulates the pancreatic ductal cell-specific keratin 19 promoter.
  • The pancreas has three distinct cell types, ductal, acinar, and islet, each with different functions.
  • Embryologically, the pancreatic and duodenal homeobox 1 (PDX1) homeodomain protein is critical for the initiation of all pancreatic lineages; however, the later differentiation of the endocrine pancreas is uniquely dependent upon high PDX1 expression, whereas PDX1 is down-regulated in the ductal and acinar cell lineages.
  • These data suggest a unifying mechanism whereby PDX1, myeloid ecotropic viral insertion site (MEIS), and pre-B-cell leukemia transcription factor 1 (PBX) may regulate ductal and acinar lineage specification during pancreatic development.
  • Specifically, concomitant PDX1 suppression and MEIS isoform expression result in proper ductal and acinar lineage specification.
  • [MeSH-minor] Animals. Base Sequence. Cell Line. DNA Primers. Genes, Reporter. Insulinoma / genetics. Insulinoma / pathology. Mice. Neoplasm Proteins / physiology

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056599.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5T32 GM 08216-19; United States / NIDDK NIH HHS / DK / P01 DK 49210; United States / NIDDK NIH HHS / DK / P30 DK 19525; United States / NIDDK NIH HHS / DK / P30 DK 50306; United States / NIDDK NIH HHS / DK / R01 DK 068157; United States / NIDDK NIH HHS / DK / R01 DK 50306
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Homeodomain Proteins; 0 / Keratin-19; 0 / Neoplasm Proteins; 0 / Trans-Activators; 0 / myeloid ecotropic viral integration site 1 protein; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down


64. Tsuta K, Ishii G, Nitadori J, Murata Y, Kodama T, Nagai K, Ochiai A: Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol; 2006 May;209(1):78-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin.
  • The latest World Health Organization (WHO) classification divides adenocarcinoma mainly into adenocarcinoma mixed subtypes, acinar adenocarcinoma, papillary adenocarcinoma, bronchioloalveolar carcinoma, and solid adenocarcinoma with mucin production, and it mentions several variants, including fetal adenocarcinoma, mucinous ("colloid") adenocarcinoma, mucinous cystadenocarcinoma, signet-ring adenocarcinoma, and clear cell adenocarcinoma.
  • In general, the mucin-producing adenocarcinoma of the lung comprises signet-ring cell carcinoma (SRCC), solid adenocarcinoma with mucin production (SA), and mucinous bronchioloalveolar carcinoma (m-BAC), mucinous ("colloid") adenocarcinomas and/or mucinous cystadenocarcinoma, and mucoepidermoid carcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Lung Neoplasms / immunology. Mucins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / immunology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Signet Ring Cell / immunology. Carcinoma, Signet Ring Cell / metabolism. Humans. Immunoenzyme Techniques. Immunophenotyping. Protein Array Analysis / methods


65. Hirota SK, Modolo F, Portela de Albuquerque MA, Lehn CN, Sugaya NN, Machado de Sousa SO, Paraiso Cavalcanti MG: Recurring acinic cell carcinoma of the buccal mucosa: a case report. Quintessence Int; 2007 Apr;38(4):289-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurring acinic cell carcinoma of the buccal mucosa: a case report.
  • A case of acinic cell adenocarcinoma of the left facial area of 10-years' duration in a 29-year-old man is presented.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Neoplasm Recurrence, Local. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432783.001).
  • [ISSN] 0033-6572
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratin-7; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Vimentin
  •  go-up   go-down


66. Tiacci E, Orvietani PL, Bigerna B, Pucciarini A, Corthals GL, Pettirossi V, Martelli MP, Liso A, Benedetti R, Pacini R, Bolli N, Pileri S, Pulford K, Gambacorta M, Carbone A, Pasquarello C, Scherl A, Robertson H, Sciurpi MT, Alunni-Bistocchi G, Binaglia L, Byrne JA, Falini B: Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. Blood; 2005 Apr 1;105(7):2812-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI.
  • Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)/mass-spectrometry analysis identified the 28-kDa protein as human tumor protein D52 (TPD52), whose expression had been previously described only in normal and neoplastic epithelia.
  • In fact, unlike other B-cell molecules (paired box 5 [PAX5], CD19, CD79a, CD20, CD22), which are down-regulated during differentiation from B cells to plasma cells, TPD52 expression reached its maximum levels at the plasma cell stage.
  • In the Thiel myeloma cell line, TPD52 bound to annexin VI in a Ca(2+)-dependent manner, suggesting that these molecules may act in concert to regulate secretory processes in plasma cells, similarly to what was observed in pancreatic acinar cells.
  • Finally, the anti-TPD52 monoclonal antibody served as a valuable tool for the diagnosis of B-cell malignancies.
  • [MeSH-major] Annexin A6 / metabolism. Calcium / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Plasma Cells / physiology
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. Antibody Specificity. B-Lymphocytes / physiology. Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Epitopes, B-Lymphocyte / immunology. Gene Expression Regulation, Leukemic / immunology. Leukemia, B-Cell / diagnosis. Leukemia, B-Cell / physiopathology. Mass Spectrometry. Mice. Mice, Inbred BALB C. Molecular Weight. Receptors, Cell Surface / immunology. Receptors, Fc

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15576473.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A6; 0 / Antibodies, Monoclonal; 0 / Epitopes, B-Lymphocyte; 0 / FCRL4 protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, Fc; 0 / TPD52 protein, human; SY7Q814VUP / Calcium
  •  go-up   go-down


67. Cui W, De Jesus K, Zhao H, Takasawa S, Shi B, Srikant CB, Liu JL: Overexpression of Reg3alpha increases cell growth and the levels of cyclin D1 and CDK4 in insulinoma cells. Growth Factors; 2009 Jun;27(3):195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Reg3alpha increases cell growth and the levels of cyclin D1 and CDK4 in insulinoma cells.
  • Regenerating gene (Reg) family protein Reg3alpha is normally expressed in pancreatic acinar and endocrine cells.
  • In order to explore its effect on islet beta-cell replication, insulinoma MIN6 cells were stably transfected with murine Reg3alpha cDNA.
  • In MTT cell proliferation assay, Reg3alpha-overexpressing cells exhibited a 2-fold increase in the rate of cell growth.
  • In order to investigate the intracellular mechanism, we studied cell cycle regulatory proteins.
  • It is established that beta-cell replication is associated with increased cyclin D1 and CDK4 levels; deficiency in CDK4 or cyclin D2 results in reduced beta-cell mass and diabetes.
  • Our results suggest that Reg3alpha stimulates beta-cell replication, by activating Akt kinase and increasing the levels of cyclin D1/CDK4.
  • [MeSH-minor] Animals. Antigens, Neoplasm. Biomarkers, Tumor. Cell Line, Tumor. Cell Proliferation. Lectins, C-Type. Mice. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19343564.001).
  • [ISSN] 1029-2292
  • [Journal-full-title] Growth factors (Chur, Switzerland)
  • [ISO-abbreviation] Growth Factors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Proteins; 0 / pancreatitis-associated protein; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / Akt1 protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.22 / Cdk4 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


68. Hasegawa M, Hagiwara S, Sato T, Jijiwa M, Murakumo Y, Maeda M, Moritani S, Ichihara S, Takahashi M: CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int; 2007 May;57(5):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CD109 gene encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface protein.
  • The anti-CD109 antibody generated by the authors was available for formalin-fixed paraffin section, and it strongly stained myoepithelial cells and basal cells but not ductal, acinar, and secretory cells in these glands.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Blotting, Western. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line. Cell Line, Tumor. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Lacrimal Apparatus / chemistry. Lacrimal Apparatus / cytology. Male. Mammary Glands, Human / chemistry. Mammary Glands, Human / cytology. Prostate / chemistry. Prostate / cytology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. RNA Interference. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Salivary Glands / chemistry. Salivary Glands / cytology. Transfection

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493171.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / CD109 protein, human; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


69. Varsegi MF, Ravis SM, Hattab EM, Henley JD, Billings SD: Widespread cutaneous metastases from acinic cell carcinoma 20 years after primary presentation. J Cutan Pathol; 2008 Jun;35(6):591-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Widespread cutaneous metastases from acinic cell carcinoma 20 years after primary presentation.
  • Acinic cell carcinoma is a rare, low-grade malignant salivary gland neoplasm.
  • We present a case of widespread cutaneous metastasis from acinic cell carcinoma arising in a 59-year-old woman with a history of acinic cell carcinoma of the parotid gland 20 years prior to her cutaneous disease.
  • To our knowledge, is the first report of widespread cutaneous metastasis from acinic cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Parotid Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cell Nucleus / pathology. Cytoplasmic Granules / pathology. Female. Humans. Middle Aged. Periodic Acid-Schiff Reaction

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261112.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Chen J, Miller EM, Gallo KA: MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene; 2010 Aug 5;29(31):4399-411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
  • Induction of MLK3 expression dramatically increases acinar size and modestly perturbs apicobasal polarity.
  • Taken together, our data show that MLK3-JNK-AP-1 signaling is critical for breast cancer cell migration and invasion.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Movement / genetics. Cell Transformation, Neoplastic / genetics. MAP Kinase Kinase Kinases / physiology. Mammary Glands, Human / pathology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Cell Culture Techniques. Cells, Cultured. Drug Evaluation, Preclinical. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Neoplasm Invasiveness. Phenotype. RNA, Small Interfering / pharmacology. Sirolimus / analogs & derivatives. Sirolimus / pharmacology. Transfection


71. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene; 2005 Jun 23;24(27):4421-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival, and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cycler quantitative polymerase chain reaction, laser-capture microdissection, and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens.
  • By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas.
  • Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Membrane Proteins / deficiency. Membrane Proteins / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. Proto-Oncogene Proteins / deficiency. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Fluorouracil / pharmacology. Humans. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856026.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNIP3 protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


72. Kim S, Welm AL, Bishop JM: A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res; 2010 Jun 15;70(12):5155-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis.
  • ING4 is a candidate tumor suppressor gene that is deleted in 10% to 20% of human breast cancers and is mutated in various human cancer cell lines.
  • To evaluate whether ING4 has a tumor-suppressive role in breast tissue, we overexpressed it in mouse mammary glands using a transplant system.
  • However, coexpression of the ING4 mutant with MYC increased the penetrance and metastasis of MYC-initiated mammary tumors, giving rise to tumors with more organized acinar structures.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):1032-8 [15882981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4324-9 [15738393.001]
  • [Cites] J Cell Sci. 2005 Jul 1;118(Pt 13):2859-69 [15976445.001]
  • [Cites] Gene. 2005 Aug 15;356:109-17 [15935570.001]
  • [Cites] Mol Cell. 2006 Jan 6;21(1):51-64 [16387653.001]
  • [Cites] Exp Cell Res. 2006 Apr 15;312(7):951-61 [16516887.001]
  • [Cites] FEBS Lett. 2006 Dec 22;580(30):6903-8 [17157298.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4464-75 [17848618.001]
  • [Cites] Cell Stem Cell. 2008 Jan 10;2(1):90-102 [18371425.001]
  • [Cites] Anat Rec (Hoboken). 2008 May;291(5):593-600 [18399550.001]
  • [Cites] J Biol Chem. 2008 Jun 6;283(23):15956-64 [18381289.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1373-9 [18375955.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(21):6632-45 [18779315.001]
  • [Cites] Cancer Lett. 2008 Nov 18;271(1):105-16 [18789575.001]
  • [Cites] Nat Cell Biol. 2008 Nov;10(11):1333-40 [18836436.001]
  • [Cites] Mol Cell. 2009 Jan 30;33(2):248-56 [19187765.001]
  • [Cites] Nat Med. 2001 Feb;7(2):235-9 [11175856.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2373-8 [12750254.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):328-32 [15029197.001]
  • [Cites] FEBS Lett. 2004 Jul 16;570(1-3):7-12 [15251430.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):409-16 [19208663.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Jun;135(6):829-35 [19034511.001]
  • [Cites] Melanoma Res. 2009 Feb;19(1):1-7 [19430401.001]
  • [Cites] J Pathol. 2009 Sep;219(1):87-95 [19479822.001]
  • [Cites] FASEB J. 1993 Jul;7(10):855-65 [8344485.001]
  • [Cites] Trends Biochem Sci. 1995 Feb;20(2):56-9 [7701562.001]
  • [Cites] Development. 1998 May;125(10):1921-30 [9550724.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16251-6 [15528276.001]
  • [Cites] Mol Biol Evol. 2005 Jan;22(1):104-16 [15356280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7481-6 [15897452.001]
  • (PMID = 20501848.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA115681; United States / NCI NIH HHS / CA / K01 CA115681-05; United States / NCI NIH HHS / CA / 5K01CA115681; United States / NCI NIH HHS / CA / 5R35CA044338; United States / NCI NIH HHS / CA / CA115681-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Homeodomain Proteins; 0 / ING4 protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ NIHMS200937; NLM/ PMC2891958
  •  go-up   go-down


73. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM: Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate; 2009 May 1;69(6):603-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
  • BACKGROUND: Small cell carcinoma of the prostate is an uncommon neoplasm, the origin of which has been controversial.
  • To address this, we performed transcriptome profiling and TP53 sequencing of concurrent small cell and prostatic adenocarcinoma to determine the relationship between these entities.
  • METHODS: We identified an unusual case of primary prostate cancer that contained adjacent acinar adenocarcinoma (Gleason score 4 + 3 = 7) and small cell carcinoma.
  • We performed laser capture microdissection to isolate tumor components and performed gene expression and TP53 gene sequence analysis on each component, with results validated by immunohistochemistry for PSA, PSAP, PSMA, androgen receptor, NKX 3.1 and neuroendocrine markers.
  • RESULTS: Transcriptome profiling of the carcinoma components identified 99 genes with a greater than 10-fold differential expression between prostatic adenocarcinoma and small cell carcinoma, many of which have not been previously reported in prostate cancer.
  • The small cell carcinoma component demonstrated upregulation of proliferative and neuroendocrine markers and tyrosine kinase receptors, and downregulation of cell adhesion molecules, supporting the aggressive nature of this form of carcinoma.
  • CONCLUSIONS: This is the first report of a primary small cell carcinoma of the prostate subjected to extensive molecular analysis and the first to show a clonal relation between two morphologically distinct prostate cancer types.
  • The evidence of progression to small cell carcinoma may yield important insights into the pathogenesis of this entity and provide a novel spectrum of molecular markers to further dissect cellular pathways important in tumor progression.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):217-27 [14695335.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):614-25 [15366705.001]
  • [Cites] Cancer. 1987 May 15;59(10):1803-9 [3030528.001]
  • [Cites] Cell. 1992 Jul 24;70(2):293-301 [1638632.001]
  • [Cites] Gastroenterology. 1994 Aug;107(2):420-8 [8039618.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):524-31 [9012485.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1574-80 [10491435.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] FASEB J. 2005 Feb;19(2):243-5 [15548588.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] J Neurosci. 2005 Nov 16;25(46):10773-85 [16291951.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):684-93 [16723845.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10683-90 [17108105.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8460-7 [17875684.001]
  • [Cites] Urol Int. 1999;62(3):133-8 [10529661.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21525-31 [10781613.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4683-8 [11406537.001]
  • [Cites] Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9 [11783945.001]
  • [Cites] Prostate. 2002 May 15;51(3):189-200 [11967953.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Prostate. 2003 Apr 1;55(1):55-64 [12640661.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • (PMID = 19125417.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058236-10; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P50 CA058236-10
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS285484; NLM/ PMC3170854
  •  go-up   go-down


74. Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH: Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol; 2005 Jun;18(6):752-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
  • Solid pseudopapillary tumor, pancreatoblastoma, undifferentiated carcinoma with osteoclastic-like giant cells, and acinar cell carcinomas are rare pancreatic nonductal neoplasms.
  • Compared to the significant advances in our understanding of the pathogenesis of pancreatic ductal adenocarcinomas in the last decades, the molecular mechanisms underlying pancreatic nonductal neoplasms are poorly understood.
  • In order to elucidate their molecular pathogenesis, we constructed tissue microarrays to study the expression of some novel pancreatic ductal adenocarcinoma-associated tumor markers in these nonductal pancreatic neoplasms.
  • We analyzed nine markers including tumor suppressor gene (14-3-3 sigma), proliferation marker (topoisomerase II alpha), epithelial markers (prostate stem cell antigen, mesothelin and cytokeratin 19), stromal markers (fascin, hsp47 and fibronectin), and gamma-synuclein whose function is not delineated.
  • In addition, we included tumor suppressor gene DPC4 and oncogene Beta-catenin to further confirm their expression in pancreatic nonductal tumors.
  • Our results showed that in contrast to pancreatic ductal adenocarcinomas that show loss of Dpc4 protein in 55% of cases, loss of Dpc4 expression is absent in pancreatic nonductal neoplasms.
  • Expression of 14-3-3 sigma is frequently seen in both pancreatic nonductal neoplasms (25-100%) and ductal adenocarcinomas (89%).
  • Aberrant nuclear expression of beta-catenin is common in pancreatic nonductal neoplasms, specifically in solid pseudopapillary tumors (88%) and pancreatoblastomas (100%) but is rarely seen in pancreatic ductal adenocarcinomas (<5%).
  • Expression of topoisomerase II alpha is not seen in solid pseudopapillary tumors and undifferentiated carcinomas with osteoclastic-like giant cells but is focally seen in pancreatoblastomas (50%) and acinar cell carcinomas (85%).
  • Expression of PSCA and mesothelin was observed in pancreatic nonductal neoplasms but their expression was seen less frequently (0-50%) and weaker than that in pancreatic ductal adenocarcinomas (60-100%).
  • CK19, a marker of pancreatic ductal adenocarcinomas, is not expressed in pancreatic nonductal neoplasms.
  • Our findings indicate pancreatic nonductal neoplasms have distinctive patterns of protein expression relative to pancreatic ductal adenocarcinomas and suggest that pancreatic nonductal neoplasms have different genetic pathways from the more common pancreatic ductal adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] 14-3-3 Proteins. Antigens, Neoplasm. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carrier Proteins / analysis. Cytoskeletal Proteins / analysis. DNA-Binding Proteins / analysis. Exonucleases / analysis. Exoribonucleases. Fibronectins / analysis. GPI-Linked Proteins. HSP47 Heat-Shock Proteins. Heat-Shock Proteins / analysis. Humans. Immunohistochemistry. Keratins / analysis. Membrane Glycoproteins / analysis. Microfilament Proteins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis. Serpins / analysis. Smad4 Protein. Synucleins. Trans-Activators / analysis. beta Catenin. gamma-Synuclein

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696124.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / Fibronectins; 0 / GPI-Linked Proteins; 0 / HSP47 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Glycoproteins; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / PSCA protein, human; 0 / SERPINH1 protein, human; 0 / SMAD4 protein, human; 0 / Serpins; 0 / Smad4 Protein; 0 / Synucleins; 0 / Trans-Activators; 0 / beta Catenin; 0 / gamma-Synuclein; 0 / mesothelin; 146808-54-0 / fascin; 68238-35-7 / Keratins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


75. Volkan Adsay N: Cystic lesions of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S71-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The names of some existing entities were revised; for example, what was known as papillary-cystic tumor is now regarded as solid-pseudopapillary tumor.
  • New entities, in particular, intraductal papillary mucinous neoplasm and its variants, such as oncocytic and intestinal subtypes were recognized.
  • Consensus criteria for the distinction of these from the ordinary precursors of adenocarcinoma, the pancreatic intraepithelial neoplasia, were established.
  • The definition of mucinous cystic neoplasms was refined; ovarian-like stroma has now become almost a requirement for the diagnosis of mucinous cystic neoplasia, and defined as such, the propensity of these tumors to occur in perimenopausal women became even more striking.
  • Greater accessibility of the pancreas afforded by improved invasive as well as noninvasive modalities has also increased the detection of otherwise clinically silent cystic tumors, which has led to the recognition of more innocuous entities such as acinar cell cystadenoma and squamoid cyst of pancreatic ducts.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486054.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR, Shah RJ: Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas; 2008 Mar;36(2):200-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some benign tissue components (intercalated cells/ducts, main pancreatic ducts, and acinar cells) were also positive for B7-H4 and/or p53.
  • [MeSH-major] Antigens, CD80 / analysis. Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / chemistry. Pancreatic Neoplasms / chemistry. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Pancreas / chemistry. Pilot Projects. Predictive Value of Tests. Reproducibility of Results. Tissue Fixation. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376314.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


77. Go JH: A spindle cell predominant pancreatic solid-pseudopapillary tumor. Yonsei Med J; 2008 Aug 30;49(4):672-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A spindle cell predominant pancreatic solid-pseudopapillary tumor.
  • A hitherto unrecognized variant of solid-pseudopapillary tumor (SPT) of the pancreas is reported.
  • The tumor presented in the pancreatic tail of a 44-year-old female patient.
  • Histologically, the neoplasm was mostly composed of sheets of spindle cells.
  • The periphery of the tumor showed typical feature of SPT.
  • Immunohistochemically, the tumor cells were positive for vimentin, CD10, CD56, beta-catenin, and alpha1-antichymotrypsin, but negative for cytokeratin, chromogranin, synaptophysin and S-100 protein.
  • Ultrastructurally, the tumor showed a few acinar spaces with microvilli between tumor cells.
  • This case is peculiar in that the tumor did not show gross cystic change and predominantly consists of spindle shaped tumor cells, so may cause difficult diagnostic problem.
  • [MeSH-major] Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1361-71 [11023097.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):818-20 [12023593.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] JOP. 2006;7(1):131-6 [16407635.001]
  • [Cites] J Surg Oncol. 2004 Mar 15;85(4):193-8 [14991875.001]
  • (PMID = 18729314.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2615298
  •  go-up   go-down


78. Viterbo D, Callender GE, DiMaio T, Mueller CM, Smith-Norowitz T, Zenilman ME, Bluth MH: Administration of anti-Reg I and anti-PAPII antibodies worsens pancreatitis. JOP; 2009 Jan 08;10(1):15-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The regeneration protein family (Reg), which includes Reg I and PAPII, is expressed in pancreas acinar cells, and increases in acute pancreatitis.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. TAUROCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2000 Mar;89(1):60-5 [10720454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8290-5 [10880565.001]
  • [Cites] J Immunol. 2008 Aug 1;181(3):1948-58 [18641332.001]
  • [Cites] Gut. 2007 Aug;56(8):1091-7 [17409121.001]
  • [Cites] Pancreas. 2007 Jan;34(1):1-14 [17198179.001]
  • [Cites] World J Gastroenterol. 2006 Jul 28;12(28):4511-6 [16874863.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):580-6 [16327837.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2005 Oct;2(10):473-83 [16224479.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):520-5 [15885230.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):254-62 [10526060.001]
  • [Cites] Clin Chim Acta. 1998 May 25;273(2):185-94 [9657348.001]
  • [Cites] Digestion. 1998;59(3):186-91 [9643677.001]
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):150-4 [10662590.001]
  • [Cites] Ann Surg. 2000 Nov;232(5):646-52 [11066135.001]
  • [Cites] J Surg Res. 2002 Jun 15;105(2):136-44 [12121700.001]
  • [Cites] J Investig Med. 2002 Nov;50(6):421-34 [12425429.001]
  • [Cites] Diabetes. 2002 Dec;51 Suppl 3:S478-83 [12475793.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):91-6 [15011837.001]
  • [Cites] Scand J Gastroenterol. 2004 Sep;39(9):870-81 [15513386.001]
  • [Cites] Biochem Biophys Res Commun. 1979 Apr 27;87(4):1176-82 [111670.001]
  • [Cites] Diabetes. 1984 Apr;33(4):401-4 [6323238.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2115-26 [3908481.001]
  • [Cites] J Clin Invest. 1986 Oct;78(4):1056-63 [2428840.001]
  • [Cites] J Biol Chem. 1988 Feb 15;263(5):2111-4 [2963000.001]
  • [Cites] Genomics. 1994 Mar 15;20(2):305-7 [8020983.001]
  • [Cites] J Gastroenterol. 1995 Oct;30(5):643-50 [8574338.001]
  • [Cites] FEBS Lett. 1995 Dec 27;377(3):429-33 [8549770.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Aug 5;225(1):16-21 [8769088.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):543-50 [9024308.001]
  • (PMID = 19129610.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK054511-05; United States / NIDDK NIH HHS / DK / R01 DK054511-04; United States / NIDDK NIH HHS / DK / DK054511-04; United States / NIDDK NIH HHS / DK / R01 DK054511-05; United States / NIDDK NIH HHS / DK / R01 DK054511-03S1; United States / NIDDK NIH HHS / DK / Z01 DK054511; United States / NIDDK NIH HHS / DK / DK054511-03S1; United States / NIDDK NIH HHS / DK / R01DK54511
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / Reg1 protein, rat; 0 / pancreatitis-associated protein; 5E090O0G3Z / Taurocholic Acid
  • [Other-IDs] NLM/ NIHMS97437; NLM/ PMC2666878
  •  go-up   go-down


79. Murtaugh LC, Leach SD: A case of mistaken identity? Nonductal origins of pancreatic "ductal" cancers. Cancer Cell; 2007 Mar;11(3):211-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this issue of Cancer Cell, Guerra and colleagues provide important new insights regarding the ability of specific pancreatic cell types to generate invasive pancreatic cancer.
  • First, they demonstrate that classical pancreatic "ductal" neoplasia can be induced by activation of oncogenic Kras in nonductal exocrine cells.
  • Second, they show that, while Kras activation in immature acinar and centroacinar cells is readily able to induce ductal neoplasia, Kras-mediated tumorigenesis in mature exocrine pancreas requires the induction of chronic epithelial injury.
  • The results shed new light on the "cell of origin" of pancreatic ductal cancer and demonstrate that chronic pancreatitis provides a permissive environment for Kras-induced pancreatic neoplasia.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Genes, ras. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology
  • [MeSH-minor] Animals. Cell Lineage. Cell Transformation, Neoplastic. Ceruletide. Humans. Mice. Mutation. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • (PMID = 17349578.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK56211; United States / NIDDK NIH HHS / DK / DK61215
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 888Y08971B / Ceruletide
  •  go-up   go-down


80. Bhattacharyya N, Fried MP: Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol; 2005 Jan-Feb;26(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaplan-Meier survival analysis was conducted for the most common tumor histologies.
  • Mean tumor size at diagnosis was 2.7 cm; 38.0% of patients had extraglandular extension of the tumor, 26.8% of patients had positive nodal disease, and 59.4% of patients received radiation therapy.
  • Tumor histology did predict survival, with squamous cell carcinoma and acinar cell carcinoma exhibiting the poorest and best survivals, respectively.
  • Stratified Cox proportional hazards modeling revealed that increasing age, tumor size, grade, extraglandular extension, and nodal positivity significantly negatively influenced survival (all P<or=.001); radiation therapy conferred a survival benefit (P=.090), whereas gender did not significantly affect survival.
  • Increasing tumor grade, nodal disease, and extraglandular extension carried particularly high hazards ratios.
  • Patients with multiple poor prognostic features such as extraglandular extension, aggressive tumor histologies, and nodal disease will exhibit poorer survivals and may be candidates for more aggressive treatment protocols.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Parotid Neoplasms / mortality
  • [MeSH-minor] Age Factors. Carcinoma, Acinar Cell / mortality. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Mucoepidermoid / mortality. Female. Humans. Male. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. SEER Program. Sex Factors. Survival Analysis. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15635580.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Al-Zaher N, Obeid A, Al-Salam S, Al-Kayyali BS: Acinic cell carcinoma of the salivary glands: a literature review. Hematol Oncol Stem Cell Ther; 2009;2(1):259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the salivary glands: a literature review.
  • Acinic cell carcinoma (ACC) is a low-grade malignant salivary neoplasm that constitutes approximately 17% of primary salivary gland malignancies.
  • The diagnosis is usually confirmed with a fine needle aspiration biopsy, and surgical excision is the main treatment of this malignant neoplasm.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063555.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 59
  •  go-up   go-down


82. Reis-Filho JS, Natrajan R, Vatcheva R, Lambros MB, Marchió C, Mahler-Araújo B, Paish C, Hodi Z, Eusebi V, Ellis IO: Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. Histopathology; 2008 Jun;52(7):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.
  • AIMS: Acinic cell carcinomas (ACCs) and secretory carcinomas (SCs) of the breast are rare, low-grade malignancies that preferentially affect young female patients.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Acinar Cell / genetics. Gene Rearrangement. In Situ Hybridization, Fluorescence. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics
  • [MeSH-minor] DNA, Neoplasm / analysis. Female. Humans

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462362.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


83. Wargo JA, Warshaw AL: Surgical approach to pancreatic exocrine neoplasms. Minerva Chir; 2005 Dec;60(6):445-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical approach to pancreatic exocrine neoplasms.
  • Pancreatic exocrine neoplasms represent a wide spectrum of pathophysiologic entities that challenge us as surgeons.
  • In this review, we will explore the contemporary clinical management of pancreatic adenocarcinoma, acinar cell carcinoma, and cystic neoplasms of the pancreas.
  • [MeSH-major] Pancreas, Exocrine / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Algorithms. Carcinoma, Acinar Cell / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma / surgery. Cystadenoma / surgery. Decision Trees. Humans. Magnetic Resonance Imaging. Neoadjuvant Therapy / methods. Neoplasm Staging. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401999.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 181
  •  go-up   go-down


84. Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK: Pancreatoblastoma in an adult: case report and review of the literature. J Gastrointest Surg; 2006 Jun;10(6):829-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An initial fine needle aspiration of the pancreatic mass was nondiagnostic, and a subsequent fine needle aspiration of a liver mass was read as metastatic acinar cell carcinoma.
  • The patient underwent a palliative resection for tumor-associated pain and gastrointestinal hemorrhage that revealed a large pancreatic tumor invading through the full thickness of the colon at the splenic flexure and adherent to the posterior gastric wall.
  • The pathology from the distal pancreatectomy, splenectomy, partial gastrectomy, partial colectomy, and cholecystectomy unexpectedly supported a diagnosis of pancreatoblastoma with evidence for squamoid corpuscles as well as areas of acinar formation.
  • During the course of his therapy, the patient's serum alpha-fetoprotein levels and serum lipase levels rose concurrently, suggesting tumor-associated production of both of these factors.
  • [MeSH-major] Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Biopsy, Fine-Needle. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Disease Progression. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Male. Middle Aged. Nausea / etiology. Neoplasm Invasiveness. Satiety Response. Splenic Vein / pathology. Splenic Vein / radiography. Stomach / pathology. Tomography, X-Ray Computed. Vomiting / etiology

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769539.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


85. Dickinson SI: Premalignant and malignant prostate lesions: pathologic review. Cancer Control; 2010 Oct;17(4):214-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High-grade prostatic intraepithelial neoplasia (HGPIN) is currently the only recognized premalignant lesion of prostatic carcinoma.
  • The criteria and clinical impact of the diagnosis of atypical small acinar proliferation on needle biopsy are reviewed.
  • Histologic variants of prostatic adenocarcinoma with distinct cell types are also described.
  • Histologic variants are recognized due to the inference of a particular Gleason grade pattern associated with the cell type, hence affecting prognosis.
  • CONCLUSIONS: HGPIN has a strong association with acinar-type prostatic adenocarcinoma.
  • HGPIN and acinar-type prostatic adenocarcinoma both show similar molecular alterations, providing further evidence of their association.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Acinar Cell / pathology. Humans. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20861809.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


86. Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S, Ooi A: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer; 2009 Jan 1;115(1):107-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In AC, the frequency of p-mTOR staining was higher in the well differentiated subtype, in particular, in the acinar structure.
  • Conversely, in squamous cell carcinomas, mTOR activation was associated with a significantly higher frequency of lymph node metastasis.
  • First, mTOR may function not only in the proliferation of tumor cells as an effector molecule downstream of EGFR but also possibly in the morphogenesis of AC.
  • Second, the activation of mTOR may play a key role in metastasis in squamous cell carcinoma.
  • [MeSH-major] Lung Neoplasms / metabolism. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Humans. Neoplasm Metastasis. Neoplasms, Squamous Cell / metabolism. Neoplasms, Squamous Cell / pathology. Phosphorylation. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Signal Transduction. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 19090006.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


87. Lin J, Jing X: Fine-needle aspiration of intrapancreatic accessory spleen, mimic of pancreatic neoplasms. Arch Pathol Lab Med; 2010 Oct;134(10):1474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of intrapancreatic accessory spleen, mimic of pancreatic neoplasms.
  • Intrapancreatic accessory spleen (IPAS) is a congenital abnormality, which mimics neoplasm.
  • Distinguishing IPAS from pancreatic neoplasm/malignancy is extremely important from a treatment perspective.
  • The image findings were highly suggestive of a pancreatic endocrine neoplasm.
  • Hematoxylin-eosin–stained cell block sections showed conspicuous thin-walled blood vessels in addition to inflammatory cells.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Spleen / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Aged. Animals. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / ultrasonography. Coloring Agents. Diagnosis, Differential. Humans. Inflammation / pathology. Inflammation / ultrasonography. Lymphocytes / pathology. Lymphocytes / ultrasonography. Male. Pancreas / anatomy & histology. Pancreas / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923303.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


88. Ebert C, Nebe B, Walzel H, Weber H, Jonas L: Inhibitory effect of the lectin wheat germ agglutinin (WGA) on the proliferation of AR42J cells. Acta Histochem; 2009;111(4):335-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rat pancreatic acinar tumour cell line AR42J is a widely used model to study the secretion, proliferation and differentiation of cells under the influence of hormones.
  • They possess both subtypes of the highly glycosylated cholecystokinin (CCK) receptor which are important for the regulation of secretion and for cell growth.
  • [MeSH-major] Cell Proliferation / drug effects
  • [MeSH-minor] Animals. Cell Line, Tumor. Flow Cytometry. Galectin 1 / pharmacology. Glycosylation / drug effects. Humans. Microscopy, Electron, Transmission. Pancreas / pathology. Pancreas / ultrastructure. Plant Lectins / pharmacology. Rats. Receptors, Cholecystokinin / chemistry. Secretory Vesicles / ultrastructure. Wheat Germ Agglutinins / pharmacology. alpha-Amylases / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195686.001).
  • [ISSN] 1618-0372
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Galectin 1; 0 / Plant Lectins; 0 / Receptors, Cholecystokinin; 0 / Ulex europaeus lectins; 0 / Wheat Germ Agglutinins; EC 3.2.1.1 / alpha-Amylases
  •  go-up   go-down


89. Ohike N, Morohoshi T: Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis. Endocr Pathol; 2005;16(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognostic significance of several pathological factors (tumor size, mitotic index, Ki-67 labeling index, and vascular invasion) and expression of exocrine markers (CA19-9, CEA, AFP, and trypsin) in pancreatic endocrine tumors was studied.
  • In one case, one-third of the tumor tissue comprised trypsin-positive cells, the outcome was comparatively poor, and the behavior of the tumor resembled that of mixed acinar-endocrine carcinoma.
  • [MeSH-major] Carcinoma, Islet Cell / secondary. Islets of Langerhans / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease-Free Survival. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000844.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


90. Heller A, Zörnig I, Müller T, Giorgadze K, Frei C, Giese T, Bergmann F, Schmidt J, Werner J, Buchler MW, Jaeger D, Giese NA: Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunol Immunother; 2010 Sep;59(9):1389-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to comprehend the spectrum of pancreatic tumor-associated antigens (pTAAs) and to assess the clinical relevance of their immunogenicity.
  • QRT-PCR and immunohistochemistry characterized PNLIPRP2 as a robust acinar cell-specific marker whose decreased expression mirrored the disappearance of parenchyma in the diseased organ, but was not related to the presence of PNLIPRP2 autoantibodies.
  • The observed pTAA spectrum comprised molecules associated with acinar, stromal and malignant structures, thus presenting novel targets for tumor cell-specific therapies as well as for approaches based on the bystander effects.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / immunology
  • [MeSH-minor] Aged. Antigens, Tumor-Associated, Carbohydrate / genetics. Antigens, Tumor-Associated, Carbohydrate / immunology. Antigens, Tumor-Associated, Carbohydrate / metabolism. Autoantibodies / blood. Cloning, Molecular. Enzyme-Linked Immunosorbent Assay. Female. Gene Library. Humans. Immunochemistry. Lipase / genetics. Lipase / immunology. Lipase / metabolism. Male. Middle Aged. Neoplasm Staging. Pancreas / metabolism. Pancreas / pathology. Prognosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514540.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Autoantibodies; 0 / MIA antigen, human; EC 3.1.1.- / pancreatic lipase related protein 2; EC 3.1.1.3 / Lipase
  •  go-up   go-down


91. Gigoux V, Clerc P, Sanchez D, Coll MG, Corominola H, Leung-Theung-Long S, Pénicaud L, Gomis R, Seva C, Fourmy D, Dufresne M: Reg genes are CCK2 receptor targets in ElasCCK2 mice pancreas. Regul Pept; 2008 Feb 7;146(1-3):88-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously demonstrated that expression of the gastrin receptor, CCK2R, in pancreatic acini of transgenic ElasCCK2 mice induced alteration of acinar morphology and differentiation, increased sensitivity to a carcinogen and development of preneoplastic lesions and tumours.
  • The expression of Reg III proteins is increased in ElasCCK2 pancreas before the development of preneoplastic lesions in a subpopulation of islet cells and in small islet-like cell clusters dispersed within the acinar tissue.
  • [MeSH-minor] Animals. Antigens, Neoplasm. Biomarkers, Tumor. Gene Expression Regulation. Glucose Tolerance Test. Immunohistochemistry. Insulin / blood. Insulin / secretion. Lectins, C-Type. Mice. Mice, Transgenic. Organ Size. Protein Array Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888528.001).
  • [ISSN] 0167-0115
  • [Journal-full-title] Regulatory peptides
  • [ISO-abbreviation] Regul. Pept.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Insulin; 0 / Lectins, C-Type; 0 / Pap protein, mouse; 0 / Proteins; 0 / Receptor, Cholecystokinin B; 0 / pancreatitis-associated protein
  •  go-up   go-down


92. Dewald GW, Smyrk TC, Thorland EC, McWilliams RR, Van Dyke DL, Keefe JG, Belongie KJ, Smoley SA, Knutson DL, Fink SR, Wiktor AE, Petersen GM: Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. Mayo Clin Proc; 2009 Sep;84(9):801-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • OBJECTIVE: To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • PATIENTS AND METHODS: Between April 4, 2007, and December 4, 2008, interphase FISH was used to study paraffin-embedded preparations of tissue obtained from 18 patients listed in the Mayo Clinic Biospecimen Resource for Pancreas Research with a confirmed diagnosis of acinar cell carcinoma, ductal adenocarcinoma, islet cell carcinoma, or pancreas without evidence of neoplasia.
  • RESULTS: FISH abnormalities were observed in 12 (80%) of 15 patients with pancreatic cancer: 5 of 5 patients with acinar cell carcinoma, 5 of 5 patients with ductal adenocarcinoma, and 2 (40%) of 5 patients with islet cell carcinoma.
  • All 3 specimens of pancreatic tissue without neoplasia had normal FISH results.
  • Gains of CTNNB1 due to trisomy 3 occurred in each tumor with acinar cell carcinoma but in none of the other tumors in this study.
  • CONCLUSION: FISH abnormalities of CTNNB1 due to trisomy 3 were observed only in acinar cell carcinoma.
  • FISH abnormalities of genes implicated in familial cancer, tumor progression, and the 5-fluorouracil pathway were common but were not associated with specific types of pancreatic cancer.


93. Fellegara G, D'Adda T, Pilato FP, Froio E, Ampollini L, Rusca M, Rindi G: Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma. Virchows Arch; 2008 Jul;453(1):107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma.
  • Here, we report the case of a 69-year-old male with a solitary neoplasm in the upper lobe of the right lung.
  • At histological examination, the tumor showed two components.
  • The main part was an adenocarcinoma of the acinar type.
  • The second part showed morphological and immunohistochemical phenotype of a neuroendocrine carcinoma composed of a small cell lung carcinoma and a large cell neuroendocrine carcinoma.
  • The aim of our study was to investigate the genetic relationship between neuroendocrine and nonneuroendocrine tumor components.
  • Microallelotyping revealed a common genetic profile in the different tumor areas.
  • These findings support the true combined nature of this exocrine-neuroendocrine carcinoma of the lung and suggest a common monoclonal origin from a pluripotent epithelial (alveolar or bronchial) precursor cell for the two different tumor components.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Small Cell / diagnosis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551311.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


94. Maiorano E, Favia G, Pece S, Resta L, Maisonneuve P, Di Fiore PP, Capodiferro S, Urbani U, Viale G: Prognostic implications of NUMB immunoreactivity in salivary gland carcinomas. Int J Immunopathol Pharmacol; 2007 Oct-Dec;20(4):779-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene numb encodes for a protein (Numb) involved in cell fate decisions in Drosophila, with proposed endocytic and developmental functions in mammalians.
  • We set out to explore the immunohistochemical expression of Numb in normal and neoplastic (28 adenoid cystic and 34 mucoepidermoid carcinomas) salivary glands, and correlated the results with the clinico-pathologic features of the neoplasms.
  • Intense Numb immunoreactivity was detected in normal ductal cells and in a subset of acinar cells.
  • In addition, while tumor grade, stage, Ki-67 and Numb immunoreactivity were associated with disease-free survival in univariate analysis, only Numb and Ki-67 immunoreactivities retained independent prognostic significance in multivariate analysis.
  • These data suggest that loss of Numb is implicated in aberrant differentiation programs of salivary gland carcinomas and may serve as a prognostic indicator in patients treated for these neoplasms.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Carcinoma, Mucoepidermoid / genetics. Membrane Proteins / genetics. Nerve Tissue Proteins / genetics. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Ki-67 Antigen / genetics. Male. Middle Aged. Parotid Gland / metabolism. Prognosis. Proportional Hazards Models. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Submandibular Gland / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179751.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Numb protein, human; 0 / RNA, Neoplasm
  •  go-up   go-down


95. Pickup M, Van der Kwast TH: My approach to intraductal lesions of the prostate gland. J Clin Pathol; 2007 Aug;60(8):856-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By current convention, all high-grade intra-acinar and intraductal neoplastic lesions of prostatic origin fall under the diagnostic umbrella term: prostatic intraepithelial neoplasm (PIN).
  • Illustrating this fact, the well-described ductal subtype of prostatic adenocarcinoma is frequently associated with conventional-type acinar adenocarcinoma, and has a tendency to propagate within adjacent intact prostatic ducts.
  • As yet, however, many of these lesions have escaped the establishment of reliable morphologic criteria or immunohistochemical differentiation for diagnosis.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor. Carcinoma, Acinar Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Male. Neoplasm Invasiveness. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):19-43 [11144897.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] Semin Urol Oncol. 1999 Nov;17(4):187-98 [10632120.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):655-65 [11041054.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):3-10 [11144902.001]
  • [Cites] Prostate. 1988;12(1):39-46 [2450341.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):619-33 [2456702.001]
  • [Cites] Semin Diagn Pathol. 1988 Aug;5(3):301-11 [2845546.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):524-34 [11505396.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):341-4 [12400988.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Prog Urol. 2004 Jun;14(3):411-3 [15373189.001]
  • [Cites] Am J Clin Pathol. 1967 Apr;47(4):497-504 [4164333.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] J Urol. 1971 Dec;106(6):892-902 [5116310.001]
  • [Cites] Cancer. 1976 May;37(5):2255-62 [130969.001]
  • [Cites] J Urol. 1979 Mar;121(3):303-5 [219263.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1566-73 [4027893.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Prostate. 1987;10(2):123-31 [2436204.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):30-6 [7802135.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):330-6 [8674012.001]
  • [Cites] Prostate. 1996 Sep;29(3):137-45 [8827081.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Hum Pathol. 1997 Feb;28(2):143-8 [9023393.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):703-7 [9477103.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):413-8 [9523662.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):46-9 [9662249.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):145-52 [9921986.001]
  • [Cites] Eur Urol. 1999;35(5-6):479-83 [10325509.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):781-5 [10403300.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1503-7 [10667430.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1039-46 [10935644.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Virchows Arch. 2005 May;446(5):511-6 [15821929.001]
  • [Cites] Hum Pathol. 2005 May;36(5):531-5 [15948120.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):646-54 [16021571.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):826-32 [17032499.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • (PMID = 17237185.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 71
  • [Other-IDs] NLM/ PMC1994484
  •  go-up   go-down


96. Ikeda C, Katakura A, Yamamoto N, Kamiyama I, Shibahara T, Onoda N, Tamura H: Nasolabial flap reconstruction of floor of mouth. Bull Tokyo Dent Coll; 2007 Nov;48(4):187-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second patient was a 74-year-old man with recurrent acinic cell carcinoma in the anterior oral floor infiltrating as far as the mandible.
  • After tumor resection, both cases had a nasolabial flap reconstruction.
  • [MeSH-minor] Aged. Carcinoma, Acinar Cell / surgery. Carcinoma, Mucoepidermoid / surgery. Follow-Up Studies. Graft Survival. Humans. Male. Mandible / surgery. Mouth Neoplasms / surgery. Neck Dissection. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360105.001).
  • [ISSN] 0040-8891
  • [Journal-full-title] The Bulletin of Tokyo Dental College
  • [ISO-abbreviation] Bull. Tokyo Dent. Coll.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Yamashita R, Matsuzaki M, Matsui T, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Clinical characteristics of prostatic adenocarcinoma with ductal features]. Nihon Hinyokika Gakkai Zasshi; 2008 Mar;99(3):525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We differentiated prostatic cases of ductal adenocarcinoma that were larger than 5 mm in diameter from cases of acinar adenocarcinomas.
  • We then examined these two groups for the pathological stages of the neoplasms and the incidence of postoperative prostate-specific antigen (PSA) failure.
  • Seven of the cases (11%) were mixed-type ductal adenocarcinomas, which contained acinar and ductal components.
  • During the follow-up period, four of the eight cases of ductal adenocarcinoma (50%) and twelve of the 56 cases of acinar adenocarcinoma (21%) showed postoperative PSA failure.
  • Compared to the cases of acinar adenocarcinoma, the cases of ductal adenocarcinoma were at a more advanced pathological stage and resulted in a higher rate of postoperative PSA failure.
  • [MeSH-major] Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404881.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


98. Luukkaa H, Laitakari J, Vahlberg T, Klemi P, Grénman R: Morphometric analysis using automated image analysis of CD34-positive vessels in salivary gland acinic cell carcinoma. Acta Otolaryngol; 2007 Aug;127(8):869-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphometric analysis using automated image analysis of CD34-positive vessels in salivary gland acinic cell carcinoma.
  • CONCLUSIONS: In computer-assisted analysis of acinic cell cancer (ACC) morphological characteristics of CD34 immunoreactivity were detected.
  • [MeSH-major] Antigens, CD34 / immunology. Carcinoma, Acinar Cell / pathology. Epithelial Cells / immunology. Image Processing, Computer-Assisted / methods. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Densitometry / methods. Female. Finland / epidemiology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging / methods. Prevalence. Prognosis

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763000.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


99. Shah S, Mortele KJ: Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, and magnetic resonance imaging features. Semin Ultrasound CT MR; 2007 Oct;28(5):357-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, and magnetic resonance imaging features.
  • Various uncommon solid pancreatic neoplasms, including exocrine and endocrine epithelial tumors, mesenchymal tumors, and metastases, are reviewed, with emphasis on key differential points, including morphologic features and patterns of contrast enhancement.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / pathology. Contrast Media. Diagnosis, Differential. Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / pathology. Humans. Lymphoma / diagnosis. Lymphoma / pathology. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Complex and Mixed / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970552.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 41
  •  go-up   go-down


100. Kuroda N, Hamaguchi N, Takeuchi E, Ohara M, Hirouchi T, Mizuno K: Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases. APMIS; 2006 May;114(5):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micropapillary carcinoma is predominantly located at the periphery of the tumor nodule or mass and occurs irrespective of the subtype of the adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Aged. Aged, 80 and over. Calcinosis / pathology. Carcinoma, Acinar Cell / pathology. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pleura / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16725015.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down






Advertisement